

**UHL Strategic Reconfiguration Business Cases**

**Name of Business Case:** **ICU ENABLER 2**  
**Vascular Angiography & VSU Full Business Case**

**Forum:** **July 30<sup>th</sup> 2015 Integrated Finance, Performance & Investment Committee**  
**August 7<sup>th</sup> 2015 Trust Board**

**Checklist Completed by:** **Nicky Topham**

**Project SRO:** **Kate Shields**

<b>Confirm Commissioner support:</b>	NHS England, as part of their regional vascular review, have instructed ULHT to identify and partner with a specialist vascular centre (Level I) to support on-going local care. ULHT have undertaken a selection process and confirmed UHL as their preferred partner going forward. This arrangement secures new patient pathways to UHL for the more complex patients; the hybrid theatre development will make sure that UHL will be able to accept all tertiary referrals. UHL are having similar discussions with the team at NGH who have agreed to formalise referral pathways to UHL for their complex patients – this arrangement fits with the stated local and national commissioning direction and will be confirmed with commissioners once the detail has been agreed.
<b>Confirm Stakeholder support:</b>	The communications plan identifies the direct involvement of health partners in the project; and the future involvement & engagement with external stakeholders including Healthwatch and the general public. Stakeholder engagement is identified in section 6.4 of the case.

		<b>Business Case Section Reference</b>
<b>What is the purpose of this project?</b>	This Full Business Case (FBC) is for the proposed development of the new vascular angiography suite at Glenfield Hospital. The development is the first key enabler of the relocation of level 3 adult critical care services within UHL.  The IFPIC and Trust Board will be requested to consider	Strategic Case 1.1

		Business Case Section Reference
	<p>and approve a business justification case for the move of level 3 adult critical care services off the LGH, in order to have assurance that the vascular cases are being considered and approved in the context as key enabling moves for the Intensive Care Unit (ICU).</p> <p>The ICU Business Justification identifies that it will be unviable to maintain the current level of critical care service at the LGH. This has been driven by the Trust's inability to sustain a workforce at the LGH past July 2016.</p> <p>Whilst the move of vascular services is expedited as a key enabler for the ICU move, the move of vascular services:</p> <ul style="list-style-type: none"> <li>• forms part of the trust's clinical strategy,</li> <li>• aligns with the UHL five year plan and is included in the trusts 5 year reconfiguration capital programme</li> <li>• is an essential move in order to maintain designation as a National Specialised Service.</li> </ul>	
<p><b>Why is it being carried out?</b></p>	<ol style="list-style-type: none"> <li>1. This is a key enabler for the move of ICU off the LGH. Vascular services are moving to the GH, and require the support of an angiography service. Whilst Cath Lab C at the GH could be used to provide this support for Vascular; if this space was used in this way, an additional suite would need to be provided for ICU dependent specialties moving from LGH to the GH. This business case therefore negates the need for this to occur.</li> <li>2. The move of vascular services to the GH is essential for the following reasons:             <ol style="list-style-type: none"> <li>a. Ensures the long term sustainability of vascular services - National Specialised Services re-designation is on-going, UHL need to attain Level One to maintain activity/reputation, this move will support this with:                 <ol style="list-style-type: none"> <li>i. Closer working relationships with</li> </ol> </li> </ol> </li> </ol>	<p>Why are we doing it? section 1.2.1</p>

		Business Case Section Reference
	<p>Cardiothoracic Services</p> <p>ii. Enables the development of a thoracic aortic disease centre with an integrated endovascular, vascular and cardiac surgical team - an increasingly important source of revenue for the Trust</p> <p>b. Increasing vascular activity due to greater prevalence of vascular disease –project provides an increase in in-patient beds</p>	
<p><b>What are the key assumptions in this business case?</b></p>	<p>Leaving the services at the LRI (the ‘Do Nothing’ option) is not viable for this project. Future designation of vascular services is dependent upon the co-location of Cardiology/Cardiothoracic services.</p> <p>The ICU cases are predicated on the provision of this angiography suite at GH; as without it the ICU dependent specialties would not have access to an angiography service.</p> <p>Additional workforce has been assumed of 0.5wte.</p>	<p>OBC Options Appraisal section 3.2</p> <p>Income &amp; Expenditure section 5.3 .1, table 23</p>

What are the Benefits?		How will it be measured?	Business Case Section Reference
<p><b>To the patient</b></p>	<ol style="list-style-type: none"> <li>Co-location with cardiology/cardiothoracic services will reduce journeys for cardiac patients who currently travel from GH to LRI for scans</li> <li>Better patient experience through improved and optimised pathways including reductions in readmissions</li> </ol>	<ol style="list-style-type: none"> <li>Patient Satisfaction / Activity Data</li> <li>Patient Satisfaction / Friends &amp; Family</li> </ol>	<p>What benefits will it bring? Section 1.2.2</p> <p>Investment</p>

What are the Benefits?		How will it be measured?	Business Case Section Reference
	3. Positioned as pre-eminent total Cardiovascular Institute serving the region and beyond	Test 3. Re-designation as Level One service	Objectives, Key Deliverables & Benefit Criteria Table 7 section 2.15
<b>To UHL</b>	1. Supports the relocation of ICU level 3 service off the LGH as the second enabling project 2. Aligns with the UHL five year plan, clinical strategy and estates development plan 3. Ensures the long term sustainability of vascular services – this move is essential for the re-designation of vascular services, allowing continuity in the provision of services and the ability to become a thoracic aortic disease centre - attracting activity and associated income	Vacant Cath Lab C at GH post Vascular move in April 2016  Commissioned vascular services	
<b>To LLR</b>	1. Patients remain in LLR for all treatment – keep funding in the local health economy	Increasing income	

		Business Case Section Reference
<b>What is the solution?</b>	<p>This business case supports the creation of a new angiography suite and vascular studies unit (VSU) with co-location of cardio-vascular services. This is supported by detailed activity modelling and new patient pathways.</p> <p>The angiography suite and vascular studies unit will be situated on the 1<sup>st</sup> Floor of the GH with close adjacencies to a newly developed vascular in-patient ward.</p> <p>Both facilities will be developed within retained estate. The angiography suite will be developed within a disused storage area which was previously</p>	The design solution section 3.3.1

		<b>Business Case Section Reference</b>
	used as the sterile services area and the VSU will be developed within disused administrative areas. The areas will be refurbished in-line with recognised compliance guidance.	
<b>What options have been considered?</b>	Whilst other options were considered, the only clinically functional solution was to place the angiography suite in the disused sterile services department.	OBC Options Appraisal Section 3.2
<b>Are there any material deviations to recommended standards?</b>	Both the Angiography Suite and the Vascular Studies Unit are being refurbished within retained estate and as such are constrained by the nature of the current building. Room sizes are denoted by m2 and have been tested with clinical and managerial stakeholders to assure the Trust that the functional area required to deliver the service against the agreed clinical model and supporting activity and capacity model is deliverable. Where the design has been constrained and HBNs and other national guidance has not been adhered to, a schedule of derogations has been developed with a brief explanation of why the derogation has been made. In all cases has been supported by the relevant Trust clinical and managerial leads; and approved by the Project Board.	Estates Annex Appendix 3
<b>How will it be implemented?</b>	The project will be managed in accordance with the principles of PRINCE2 methodology. The project managers will have support from the capital projects team, and external consultants.	Project Plan Section 6.3
<b>Are there any key dependencies?</b>	Internal: The purchase order for this project needs to be placed on Monday 10th August. Whilst discussions are on-going with the NTDA regarding accessing money as part of our capital plan, we need to be able to access capital immediately in order to commence works.	
	External: The long term access to capital will require the NTDA support of our ITFF application to access funds.	

			Business Case Section Reference
<b>When will it be completed?</b>	<b>Milestone</b>	<b>Date</b>	Project Programme section 6.3.1
	Finance & Performance Committee support for FBC to be approved by TB (FBC document)	July 30 <sup>th</sup> 2015	
	Trust Board Approval of FBC	August 6 <sup>th</sup> 2015	
	Construction Commences	October 2015	
	Handover	April 2016	
<b>How much will it cost?</b>	<p>The capital cost of the Angiography suite is estimated to be £4.2 million outturn (including VAT).</p> <p>The revenue position of the scheme is a net increase in cost of circa £70,000. This assumes additional income of £88,000 netted off by interest and capital charges and the cost of a technician.</p>		<p>Capital Costs section 5.2</p> <p>Income &amp; expenditure section 5.3</p>
<b>Will it be affordable?</b>	<p>The development causes a small net recurrent increase in revenue costs of c£70k per annum.</p> <p>The Trust Financial Strategy, approved by the Trust Board on 4th June 2015, assumes that the operating cost impact of site reconfiguration will be zero and the non-operating costs impact will be as per the capital programme. The Trust Financial Strategy therefore includes these costs.</p>		Affordability section 5.5
<b>How will the project contribute to deficit reduction?</b>	<p>The project will:</p> <ul style="list-style-type: none"> <li>• Help enable the Trust's preferred option to move acute services off the Leicester General Hospital which is key to eliminating the structural deficit.</li> <li>• Help increase market share with co-location to cardiac services and improved facilities for undertaking quaternary activity</li> </ul>		
<b>How have patients been</b>	During July/August 2013 a public engagement / consultation exercise was undertaken with both		Stakeholder Engagement

Paper H

		Business Case Section Reference
<b>involved?</b>	patients and members of staff to assess support for the Trust's plans for a single site take for Surgery. In addition there were specific questions relating to the vascular services transfer. Both paper and online surveys were undertaken which supports this approach.	section 2.14 & 6.5
<b>What external assurance has been obtained?</b>	<p>A Health check level 3 review was undertaken on the 6-8th July, previously known as a Gateway Level 3, on the vascular and ICU projects.</p> <p>The outcome of this was an AMBER rating reflecting that successful delivery appears feasible but issues require management attention. The issues appear resolvable at this stage of the programme/project if addressed promptly.</p> <p>With regards to the vascular projects, whilst the review team supported the need to create a cutting edge and comprehensive centre for cardio-vascular medicine and research on a single site at Glenfield, they were concerned that the capital and workforce costs needed to be finalised prior to submission to IFPIC. These are now final as reflected in the FBC.</p>	External review section 6.11


Risks (scoring over 15) & Mitigations			RAG	Business Case Section Reference
<b>Financial</b>	<p>Inability to secure necessary funding / funding shortfall.</p> <p>Purchase order needs to be raised by 10<sup>th</sup> August to maintain programme.</p>	<p>Discussion with the NTDA, the Executive Team, IFPIC and Trust Board to access funds from trust capital programme whilst the funding application process progresses to obtain external funds.</p> <p>This business case needs to be approved to obtain access to</p>	15	

Risks (scoring over 15) & Mitigations			RAG	Business Case Section Reference
		funding via ITFF application.		
<b>Operational</b>	The challenging programme does not allow for delay in the construction programme. The impact of delay past April 2016 would risk delivery of the ICU move by July 2016.	At this point the programme is deemed to be achievable, but will be monitored closely.	15	
<b>Workforce</b>	None scoring over 15			
<b>Estates</b>	Unforeseen Asbestos within existing fabric of existing building.	There is always a risk that the asbestos survey will miss asbestos in seals to ducts – a contingency plan will be developed	16	
<b>Equipment &amp; Procurement</b>	None scoring over 15			
<b>Comms &amp; Engagement</b>	None scoring over 15			
<b>Stakeholder Ownership</b>	None scoring over 15			
<b>Project Delivery</b>	None scoring over 15			
<b>IM&amp;T</b>	None scoring over 15			
<b>Training</b>	None scoring over 15			



RAG Rating Key for Risks

		Impact					
		Very Low	Low	Medium	High	Very High	
		1	2	3	4	5	
Probability	Very Low	1	1	2	3	4	5
	Low	2	2	4	6	8	10
	Medium	3	3	6	9	12	15
	High	4	4	8	12	16	20
	Very High	5	5	10	15	20	25



**Full Business Case**  
**ICU Enabler 2:**  
**Angiography Suite &**  
**VSU**  
July 2015

Version    **FINAL 1.9**  
Issue date    **31<sup>st</sup> July 2015**

*Building Caring at its best*

# Document Quality Management

**Title** ICU Enabler 2: Angiography Suite & VSU Full Business Case

**Date** 31<sup>st</sup> July 2015

**Drafted by** Neal James, Project Manager, UHL

**Checked by** Anna Fawcett, Business Case Manager, UHL

**Authorised by** Nicky Topham, Head of Strategic Reconfiguration Business Cases, UHL

## Document History

Version	Date Issued	Brief Summary of Change	Author
1.0	10/06/15	Separation of Vascular OBC/FBC to component parts to accelerate delivery	NJ
1.1	23/06/15	Completion of Communication and stakeholder section	RP/NJ
1.2	2/07/15	Refresh of Economic section	TP/NJ
1.3	2/07/15	Refresh finance section	TP/NJ
1.4	7/07/15	Review narrative	NJ
1.5	13/07/15	Refresh finance and economic sections	TP/NJ
1.6	21/07/15	Formatting update and content review	AF
1.7	23/07/15	Addition of final narrative, check of referencing and final formatting	AF
1.8	23/07/15	Content update review	NT
1.9	31/07/15	Financial updates following IFPIC review	TP

# Glossary of Terms

Abbreviation	Full Heading
<b>ALOS</b>	Average length of stay
<b>BCT</b>	Better Care Together
<b>BREEAM</b>	Building Research Established Environment Assessment
<b>BRU</b>	Biomedical Research Unit
<b>CCG</b>	Clinical Commissioning Group
<b>CDM</b>	Construction, Design Management
<b>CMG</b>	Clinical Management Group
<b>DCP</b>	Development Control Plan
<b>DH</b>	Department of Health
<b>DQI</b>	Design Quality Indicator
<b>EVAR</b>	Endo-Vascular Arterial Repair
<b>FBC</b>	Full Business Case
<b>FOT</b>	Fore-cast Out-turn
<b>FM</b>	Facilities Management
<b>GEM</b>	Generic Economic Model
<b>GH</b>	Glenfield Hospital
<b>GMP</b>	Guaranteed Maximum Price
<b>H&amp;S</b>	Health & Safety
<b>HBN</b>	Hospital Building Notes
<b>HTM</b>	Hospital Technical Memorandum
<b>I&amp;E</b>	Income & Expenditure

Abbreviation	Full Heading
IBP	Integrated Business Plan
IM&T	Information Management & Technology
IP	Infection Prevention
KPI	Key Performance Indicator
LCC	Leicester City Council
LLR	Leicester, Leicestershire & Rutland
LOS	Length of Stay
LPT	Leicester Partnership Trusts
LRI	Leicester Royal Infirmary
LTFM	Long-term Financial Model
MES	Managed Equipment Service
NIHR	National Institute of Health Research
NSF	National Service Framework
NTDA	NHS Trust Development Authority
OBC	Outline Business Case
OJEU	Official Journal of the European Union
OSC	Overview Scrutiny Committee
PPE	Post Project Evaluation
PPI	Patient Public Involvement
PSCP	Principle Supply Chain Partner
SOC	Strategic Outline Case
TVAR	Thoracic Endovascular Aortic repair
UHL	University Hospitals Leicester
VFM	Value for Money
VSU	Vascular Studies Unit

Abbreviation	Full Heading
YTD	Year to Date

## Contents

Document Quality Management .....	2
Document History .....	2
Glossary of Terms .....	3
<b>1   Executive Summary.....</b>	<b>9</b>
1.1 Introduction .....	9
1.2 Strategic Case .....	11
1.3 Economic Case.....	12
1.4 Commercial Case.....	13
1.5 Financial Case .....	15
1.6 Management Case.....	16
1.7 Conclusion .....	17
1.8 Recommendation.....	18
<b>2   The Strategic Case.....</b>	<b>19</b>
2.1 Introduction .....	19
2.2 Structure & Content of the Document.....	19
<b>Part A: The Strategic Context .....</b>	<b>21</b>
2.3 Introduction .....	21
2.4 Organisational Overview & Background.....	21
2.5 The Glenfield Hospital Site.....	23
2.6 Background to the Redevelopment Requirement.....	23
2.7 Existing Arrangements .....	24
2.8 Strategy .....	24
2.9 Summary .....	34
<b>Part B: The Case for Change .....</b>	<b>36</b>
2.10 Introduction .....	36
2.11 Clinical Drivers for Change.....	36
2.12 Current Activity & Demand.....	36
2.13 Constraints and Dependencies .....	37

2.14	Stakeholder Engagement.....	37
2.15	Investment Objectives, Key Deliverables & Benefits Criteria .....	39
2.16	Benefits Realisation .....	43
2.17	Potential Business Scope & Key Service Requirements .....	43
2.18	Summary .....	43
<b>3  </b>	<b>The Economic Case .....</b>	<b>45</b>
3.1	Introduction .....	45
3.2	OBC Options Appraisal .....	45
3.3	The Preferred Option .....	51
<b>4  </b>	<b>The Commercial Case .....</b>	<b>54</b>
4.1	Introduction .....	54
4.2	Procurement Strategy .....	54
4.3	Risk.....	55
4.4	Proposed Charging Mechanisms .....	56
4.5	Proposed Contract Lengths.....	56
4.6	Financial Reporting Standard 5 Accountancy Treatment.....	56
<b>5  </b>	<b>The Financial Case.....</b>	<b>58</b>
5.1	Introduction .....	58
5.2	Capital Costs.....	58
5.3	Income and Expenditure .....	60
5.4	Impact on Trust Income, Cash Flow & Balance Sheet.....	62
<b>6  </b>	<b>The Management Case .....</b>	<b>64</b>
6.1.	Introduction .....	64
6.2.	Project Governance Arrangements .....	64
6.3	Project Plan.....	69
6.4	Use of Special Advisors .....	69
6.5	Stakeholder Engagement.....	70
6.6	Outline Arrangements for Change & Contract Management.....	71
6.7	Outline Arrangements for Benefits Realisation .....	72
6.8	Outline Arrangements for Risk Management.....	72
6.9	Outline Arrangements for Post Project Evaluation.....	74
6.10	Contingency Plans .....	74
6.11	External Review .....	75
	<b>Appendices.....</b>	<b>76</b>

## Figures and Tables

Table	Details
1	Service Efficiencies
2	Financial Position
3	Capital Cost Summary
4	Project Programme
5	Strategic Guidance
6	Patient Survey Response
7	Investment Objectives and Wider Benefits Realisation Plan
8	OBC Economic Appraisal Summary
9	Combining the OBC Financial and Non-Financial Scores
10	Vascular Capital Costs for the Hybrid Theatre, Vascular Ward, Angiography Suite & Vascular Studies Unit at OBC & FBC
11	Angiography & VSU Capital Costs at OBC & FBC
12	OBC Revenue Costs for all Vascular Services
13	FBC Revenue Costs for all Vascular Services
14	OBC Revenue Costs for Angiography & VSU
15	FBC Revenue Costs for Angiography & VSU
16	Changes between OBC and FBC
17	Key External Advisors & Construction Services
18	Summary of Capital Costs
19	Recoverable VAT
20	Capital Charge Impact of Scheme (IBD)
21	Capital Charge Impact of Scheme (PDC)
22	Impact on Trust's Balance Sheet
23	Value of Impairments
24	Vascular Project Board
25	Work Streams & Deliverables
26	Project Milestones
27	External Advisors



Figure	Details
1	Leicester Region
2	Better Care Together Case for Change
3	Trust Strategic Objectives
4	Caring at its Best
5	UHL's Quality Commitment
6	Vascular Angiography & VSU Project Structure

# 1 | Executive Summary

## 1.1 Introduction

This Full Business Case (FBC) is for the proposed development of an Angiography Suite and Vascular Studies Unit (VSU) at Glenfield Hospital (GH). The development is the second key enabler of the relocation of Level 3 Intensive Care Unit (ICU) off the Leicester General Hospital (LGH) onto the Leicester Royal Infirmary (LRI) and Glenfield Hospital (GH).

### 1.1.1 ICU Imperative

Whilst there is a good quality and safe Level 3 ICU service at present at the Leicester General Hospital (LGH), the Department of Critical Care Medicine (DCCM) has experienced medical staff recruitment and retention issues across all grades, which will make it unviable to maintain the current level of critical care service in the future. This has been driven by:

- ▶ Reduced dependency required within the critical care patient population at the LGH due to previous service moves at UHL. This restricts opportunities for critical care staff to maintain experience in providing care for the most critically ill patients and is a threat to the safety of the service in the near future.
- ▶ Due to the acuity of patients, the middle grade rota at the unit at the LGH can no longer be filled with suitable 'trainee' posts. The rota is therefore being filled by higher staff grades at an increased cost.
- ▶ Recruitment to substantive consultant intensivist posts at the LGH has been attempted on multiple occasions but has failed, largely due to the loss of training designation and the reduction in patient acuity. A national shortage of experienced critical care nursing and medical staff (coupled with retirement of several existing experienced consultant staff) has compounded recruitment problems.

If the Level 3 ICU beds are not moved, intensive care will be forced to stop at LGH past July 2016. This will have an immediate impact of UHL's ability to undertake Level 3 ICU dependant surgery at the LGH site and as such surgery will be stopped. The impact will be the need for patients requiring such procedures to travel out of county to other providers. This will have an adverse impact on UHL's reputation and quality of care for patients.

### 1.1.2 An ICU Enabler

This is a key enabler for the move of ICU off the LGH. Vascular services are moving to the GH, and require the support of an angiography service. Whilst the Cath Lab C at the GH could be used to provide this support for Vascular; if this space was used in this way, an additional suite would need to be provided for ICU dependent specialties

moving from LGH to the GH. This business case therefore negates the need for this to occur.

### 1.1.3 An Improvement to the Vascular Service

UHL's Vascular Surgery Unit is one of the UK's premier units providing high-quality care for patients with peripheral vascular diseases. It is staffed by a multidisciplinary team of nurses, occupational therapists, physiotherapists, radiologists, anaesthetists and surgeons working to achieve excellent patient outcomes. This is evidenced by both local patient survey data<sup>1</sup> and national audit outcome data<sup>2</sup>. Furthermore, the unit has a strong track-record of innovation and research, from the invention of sub-intimal angioplasty<sup>3</sup> to the early implementation and refinement of endovascular aneurysm repair<sup>4</sup>, and more recently leading worldwide collaborative research projects that have both informed clinical care pathways<sup>5</sup> and identified new paradigms for the basis of aneurysmal disease<sup>6</sup>.

Despite this record of excellence there are significant challenges facing UHL's Vascular Unit. The provision of many aspects of vascular surgery now falls under the remit of specialised commissioning groups and there is a national move to locate tertiary services in fewer, larger units (level one centres). In order to ensure the long-term survival of the vascular unit and build upon the current success it is necessary to invest in the development of the service and thus place the unit at the forefront of both regional and national contenders to continue providing vascular services. In particular, it is necessary to provide the infrastructure (both material and human resources) to be able to build upon the current tertiary referral practice and develop a quaternary referral practice.

The principal barriers to moving the current service forward are;

- ▶ The current location of the service at the LRI site, separate from cardiac and cardio-thoracic surgery, both of which are at the GH
- ▶ The lack of angiography facilities to further develop vascular services.

Both the co-location of vascular surgical services with cardio-thoracic surgery and the provision of all vascular component services (including an angiography suite) are pre-requisites for the commissioning of complex vascular surgery<sup>7</sup>.

---

<sup>1</sup>Ward 21 Friends and Family Test

<sup>2</sup>Vascular Society of Great Britain and Ireland. National Vascular Registry 2013 Report on Surgical Outcomes, Consultant-level Statistics. <http://www.vsgip.org.uk/surgeon-level-public-reporting/> [accessed 1 June 2014].

<sup>3</sup>Recanalisation of femoro-popliteal occlusions: improving success rate by subintimal recanalisation. Bolia A, Brennan J, Bell PR. Clin Radiol. 1989 May;40(3):325

<sup>4</sup>Endovascular stenting of abdominal aortic aneurysms. Sayers RD, Thompson MM, Bell PR. Eur J Vasc Surg. 1993 May;7(3):225-7.

<sup>5</sup>Surveillance intervals for small abdominal aortic aneurysms: a meta-analysis. RESCAN Collaborators: Bown MJ, Sweeting MJ, Brown LC, Powell JT, Thompson SG. JAMA. 2013 Feb 27;309(8):806-13

<sup>6</sup>Abdominal aortic aneurysm is associated with a variant in low-density lipoprotein receptor-related protein 1. Bown MJ et al. Am J Hum Genet. 2011 Nov 11;89(5):619-27

<sup>7</sup>NHS England. 2013/14 NHS Standard Contract for Specialised Vascular Services (Adults). <http://www.england.nhs.uk/wp-content/uploads/2013/06/a04-spec-vascu-adult.pdf> [accessed 1 June 2014].

## 1.2 Strategic Case

The Trust's vision is to create a comprehensive centre for cardiovascular medicine and research. In moving the vascular surgery unit to the GH site, this brings together not only the clinical services, but also the strong academic components of these services. This will build upon the previous investments in the National Institute of Health Research (NIHR) Leicester Cardiovascular Biomedical Research Unit (BRU) and the British Heart Foundation Cardiovascular Research Centre and strengthen the world-leading position of Leicester as a centre for cardiovascular research excellence.

### 1.2.1 Why are we doing it?

- ▶ A key component and enabler of the level 3 ICU moves will be the transfer of Vascular Services from the LRI
- ▶ The co-location and integration with cardiology/ cardiothoracic surgery services at the GH will establish a dedicated vascular inpatient service on one site.
- ▶ It will transform the scope and quality of vascular service for both patients and staff and support UHL's ambition to be recognised as a Level One regional centre for complex endovascular services through:
  - ◆ Closer working relationships with Cardiothoracic Services
- ▶ Vascular activity is increasing due to greater prevalence of vascular disease.
- ▶ The ongoing National Specialised Services re-designation creates a need for the Trust to attain Level One to maintain its activity/reputation.
- ▶ It ensures the long term sustainability of vascular, cardiac and cardiology services – no change in the current service provision would result in a major risk of loss of designation and the secondary effects of this on cardiovascular services as a whole.
- ▶ A key consideration for future designation as a thoracic aortic disease centre will be the requirement for an integrated endovascular, vascular and cardiac surgical team. The development of an integrated aortic disease service will form an increasingly important source of revenue for the Trust as other procedures e.g. coronary artery bypass grafts (currently 50% of income) declines
- ▶ It aligns with the Trust's Five Year Integrated Business Plan, Clinical Strategy and Estate Development Strategy.

### 1.2.2 What benefits will it bring?

- ▶ A comprehensive programme to clinically manage and surgically treat patients with aortic pathology, which is a primary aim of the cardiac, thoracic and vascular surgeons and is reflected in the Five Year IBP to be realised in the next two years.
- ▶ Cost Efficiencies through streamlined patient processes
- ▶ Future-proofed, updated facilities
- ▶ Better quality and safety of care provided
- ▶ First step in Trust's strategy towards achieving a two site solution
- ▶ Enhanced staff recruitment, development and retention
- ▶ Alignment of clinical and research facilities on the GH site. Cardiovascular research has been a major strength of the Leicester Medical School, University of Leicester (UoL) since its inception. This was recognised through the award of a National Institute of Health Research (NIHR) Biomedical Research Unit (BRU) in cardiovascular disease to a partnership between UHL and UoL. The BRU has state of the art facilities for clinical research on the GH site. The opening of the £12m Cardiovascular Research Centre (CRC) at GH further re-enforces the centralisation of services on the GH site

### 1.2.3 Can we afford it?

- ▶ The capital costs are £4.16m. This is accounted for in the Trust's approved Capital programme over the next two financial years

## 1.3 Economic Case

The options appraisal process at OBC stage was combined across all components of the vascular service move. This FBC sets out the details for the preferred option for the Angiography Suite and VSU, which comprised:

- ▶ Option A – refurbishment of existing space on the first floor at Glenfield Hospital.

Since OBC, capital costs have increased by 24% (outturn) and 6% (approval sum). The increased capital has had a marginal impact on the revenue position compared to the OBC. Examined in the context of the overall Vascular capital costs, there is no circumstance where the other options in the OBC options appraisal would now be preferred to the current option, and as a result of this the options appraisal has not been revisited.

The 'Do Nothing approach' is not a viable solution for this project. Future designation of vascular services is dependent upon the co-location of Cardiology/Cardiothoracic services. The 'Do Nothing' option (i.e. not transferring the service) not only jeopardises

the future provision of vascular services at UHL but also impacts upon UHL's site wide reconfiguration programme of which this project is seen as a key enabler.

The creation of a vascular angiography facility contributes towards the following service efficiencies:

*Table 1 Service Efficiencies*

Efficiencies	Measured
Reduced average length of stay (including pre and post-op LOS)	Activity Data
Increase in minimally invasive procedures reduces time spent in Critical Care beds	Activity Data
Co-location with cardiology/cardiothoracic services will reduce journeys for cardiac patients who currently travel from GH to LRI for scans	Patient Satisfaction / Activity Data
Better patient experience through improved and optimised pathways including reductions in readmissions	Patient Satisfaction / Friends & Family Test
Positioned as pre-eminent total Cardiovascular Institute serving the region and beyond	Re-designation as Level One service

## 1.4 Commercial Case

The project required the provision of, and procurement of one key service:

► Construction services

As part of the FBC development, the Trust decided that the scheme would be procured through UHL's framework partnership with Interserve Facilities Management (IFM) and assigned to Interserve Construction Limited. UHL followed procurement regulations and law to establish the framework which is headed in contract between the Trust and IFM. IFM were appointed following an OJEU process with reference: OJ/S S139, 22/07/2011, 231138-2011-EN.

Under the bespoke framework, Interserve Construction Ltd is appointed as principal contractor for the delivery of projects; commercial arrangements and contracts are pre-agreed to cover commissioning of the business case through to final delivery of the asset using an NEC3 Option C Form of Contract (Target Contract with Activity Schedule). Cost savings are split between the Trust and the Client based on previously agreed percentages which engenders a spirit of partnering and collaboration within the Project Team. The risk of cost overrun is transferred to Interserve once the Guaranteed Maximum Price (GMP) has been agreed and construction stage commenced.

Project risk is dealt with openly from the outset of the project and the client; Interserve Construction Ltd and the Design Team are encouraged to take an active role in

identifying, mitigating and apportioning risk to the party best suited to deal with it. This should be a proactive process throughout the delivery of the project.

Under the framework, Interserve has:

- ▶ Taken single point responsibility to manage the design and construction process from completion of OBC through FBC to project completion
- ▶ Assembled a dedicated team from its supply chain of experienced health planners, designers and specialists, to successfully deliver facilities that will benefit patients and staff alike
- ▶ Provided benefits of experience of long term partnering arrangements that will continue throughout the life of the project
- ▶ Committed to identifying construction solutions that will assist in the implementation of improved service delivery, best practice and delivering best value

Interserve and UHL have worked together through the FBC stage to develop and agree a guaranteed maximum price for delivery of the scheme. This reflects:

- ▶ Fees for professional advice such as design and cost management
- ▶ Market tested packages for construction works on an open book basis

The GMP will be assessed for overall value for money and affordability by cost consultants acting for UHL (Rider Levett Bucknall - RLB). This will take into account elements such as:

- ▶ Prevailing rates for similar works nationally and locally
- ▶ Published cost indices
- ▶ Knowledge of the cost of work in the hospital from other recent schemes
- ▶ Prime contractor and client retained risks as identified in the joint risk register

It was agreed that the development of the GMP would be run in parallel with the development of the Works Information and this would be undertaken in a fully open book / collaborative environment, such that a minimum of three quotations would be obtained for all Works Packages making up at least 80% of the GMP.

Package responses were assessed by Interserve Construction Ltd in conjunction with the Trust's advisors RLB to ensure the 'Best Value' tender was included in the GMP. The assessment was not only going to be based on price but also programme, design / technical proposals and likely risk. Interserve and RLB agreed a formal assessment proposal for each package. Tenders were benchmarked appropriately.

### 1.4.1 Equipment Procurement Strategy

At OBC stage it was described that the angiography suite & VSU would be a transfer of services from LRI to Glenfield, including a transfer of angiography equipment. This equipment forms part of an existing arrangement with Astral for Managed Equipment

Service (MES). Further review of other requirements has concluded that the transfer of some equipment would not be practical; therefore a nominal component of the equipment budget has been set aside for new equipment. This will be procured via the Trust.

## 1.5 Financial Case

The financial position of the vascular angiography suite and VSU business case shows an additional cost of £70,000 per annum. This is shown in the following table:

Table 2 Financial Position

Baseline Costs	2015/16	2016/17	2017/18	2018/19	2019/20	2020/21
<b>Income</b>						
Vascular Tariff	7,493	7,493	7,493	7,493	7,493	7,493
<b>Total Income</b>	<b>7,493</b>	7,493	7,493	7,493	7,493	7,493
<b>Expenditure</b>						
Current Staff	3,699	3,819	3,819	3,819	3,819	3,819
Current Non pay	1,539	1,539	1,546	1,546	1,546	1,546
Current FM costs	102	102	102	102	102	102
Current Support costs	2,757	4,132	4,012	4,012	2,757	2,757
<b>Total Expenditure</b>	<b>8,097</b>	<b>9,591</b>	<b>9,479</b>	<b>9,479</b>	<b>8,224</b>	<b>8,224</b>
<b>Overheads</b>	<b>2,216</b>	<b>2,296</b>	<b>2,297</b>	<b>2,293</b>	<b>2,289</b>	<b>2,285</b>
<b>Total Current Costs</b>	<b>(2,819)</b>	<b>(4,394)</b>	<b>(4,282)</b>	<b>(4,278)</b>	<b>(3,019)</b>	<b>(3,015)</b>
Angiography Income and Costs	2015/16	2016/17	2017/18	2018/19	2019/20	2020/21
<b>Additional Income</b>		<b>88</b>	<b>88</b>	<b>88</b>	<b>88</b>	<b>88</b>
<b>Recurrent Costs</b>						
Vascular and Support Staffing		22	22	22	22	22
Non Pay		21	21	21	21	21
<b>Total Recurrent Costs</b>		<b>52</b>	<b>52</b>	<b>52</b>	<b>52</b>	<b>52</b>
<b>Depreciation &amp; Capital Charges</b>						
Change in Depreciation		15	15	15	15	15



Interest Payable	23	94	95	91	86	82
<b>Total Depreciation &amp; Capital Charges</b>	<b>23</b>	<b>108</b>	<b>109</b>	<b>105</b>	<b>101</b>	<b>97</b>
<b>Total Additional Cost</b>	<b>23</b>	<b>72</b>	<b>73</b>	<b>69</b>	<b>65</b>	<b>61</b>

The Trust Financial Strategy, approved by the Trust Board on 4<sup>th</sup> June 2015, assumes that the operating cost impact of site reconfiguration will be zero and the non-operating costs impact will be as per the capital programme. It therefore includes all of these costs.

### 1.5.1 Capital Costs

The capital costs of the Vascular Angiography Suite and VSU total **£4,164,902** including forecast out-turn inflation. Below is an analysis of the total costs.

Table 3 Capital Cost Summary

Capital Costs	£
Construction	2,184,254
Fees	456,053
Non Works Cost	335,183
Equipment	118,158
Planning Contingency	117,331
Optimism bias	113,090
<b>Sub Total</b>	<b>3,324,069</b>
Inflation	840,833
<b>Total</b>	<b>4,164,902</b>

### 1.5.2 Workforce Plan

The workforce change in this business case is minimal, and only reflects an additional 0.5 WTE Band 7 post.

## 1.6 Management Case

The programme is set out below:

Table 4 Project Programme

Milestone	Date
Integrated Finance, Performance & Investment Committee support for FBC to be approved by Trust Board	July 30 <sup>th</sup> 2015
Trust Board Approval of FBC	August 6 <sup>th</sup> 2015
Purchase Order placed for construction	August 10 <sup>th</sup> 2015
Construction Commences	October 2015
Handover	April 2016

The project will be managed using PRINCE 2 compliant methodology and project management tools such as Gantt charting and critical path analysis. Project direction and management will be determined by the Project Board.

## 1.7 Conclusion

This business case is a central key enabler to the realisation of the interim reconfiguration of Level 3 ICU services off the LGH site and the vision of co-located specialist and tertiary services on the GH site. This is a key move in the Trust's Five Year Strategy. Each of these objectives link to the long-term strategy of the service and the wider Trust:

- ▶ A comprehensive integrated vascular, cardiology and cardiac surgery service will provide the best possible care to patients with cardiovascular disease.
- ▶ Vascular service re-designation and aortic service designation
- ▶ Improved efficiencies through dedicated vascular imaging capacity
- ▶ Increasingly complex activity undertaken generating additional income for the Trust
- ▶ Redevelopment and increased capacity providing opportunities for the Trust to fulfil the Trusts overall strategic transformation programme
- ▶ A safe and robust service for the management of Level 3 ICU services at UHL
- ▶ On-going business continuity of ICU services

The costs associated with this service move are:

- ▶ Capital Costs: £4.16m (accounted for in approved Capital Programme 14/15 & 15/16)
- ▶ Revenue Costs: £61,000
- ▶ Loss of Status without re-designation: not financially quantifiable

The key actions and decisions required to realise this vision are:

- ▶ Support for the capital investment
- ▶ Support for the additional revenue costs recognising that a significant amount are for a limited time only

## 1.8 Recommendation

The Trust Board is recommended to approve this business case

Signed: .....

Senior Responsible Owner

Date:.....

Senior Responsible Owner  
Project Team

## 2 | The Strategic Case

### 2.1 Introduction

This section sets the strategic case for change, i.e. why the project investment is required, with reference to:

- ▶ How it fits with national, local and Trust policies
- ▶ The problems that will be addressed
- ▶ How it will meet Trust needs and objectives
- ▶ How it will realise the outcomes and benefits, as well as the associated risks

2

2.1

#### 2.1.1 Clinical objectives of the project

- ▶ To continue to safely provide the best care for the most critically ill patients
- ▶ To meet increasing demand for vascular services which is greater than the current capacity can provide. Historic trends in growth suggest a 5% annual growth in vascular services
- ▶ Requirement for single site vascular and cardio-thoracic departments that incorporates key adjacencies and presence of diagnostics and medical assessment services. This enables implementation of the developed model of care for adults accessing this service
- ▶ Changes in the local and national demographics combined with the Trust's plan to develop a level 1 Vascular Centre for Leicester is impacting on increased demand
- ▶ Redevelopment and increased capacity will provide opportunities for the Trust to fulfil its strategic redevelopment programme

### 2.2 Structure & Content of the Document

This business case has been prepared using the agreed standards and format for business cases, as set out in DH guidance and HM Treasury Green Book. The case comprises the following key components:

- ▶ **The Strategic Case** | This sets out the strategic context and the case for change, together with the supporting investment objectives for the scheme

- ▶ **The Economic Case** | This demonstrates that the organisation has selected the choice for investment which best meets the existing and future needs of the service and optimises value for money (VFM)
- ▶ **The Commercial Case** | This outlines the content and structure of the proposed deal
- ▶ **The Financial Case** | This confirms funding arrangements and affordability and explains any impact on the balance sheet of the organisation
- ▶ **The Management Case** | This demonstrates that the scheme is achievable and can be delivered successfully to cost, time and quality

# Part A: The Strategic Context

## 2.3 Introduction

This section provides an overview of the context in which the Trust provides its services and the strategic guiding principles, directives and policies that ensure clinical quality standards are met. The intention is to provide an overview of the Trust and its strategic objectives, to highlight current vascular angiography and VSU service delivery and set the context for this business case. It also provides an overview of the driving policies and guidance documents at National, Regional and Local level.

## 2.4 Organisational Overview & Background


### 2.4.1 University Hospital Leicester NHS Trust

UHL is one of the largest teaching hospitals in the country and operates across three main sites; the Leicester Royal Infirmary, Leicester General Hospital, and the Glenfield Hospital.

#### Local Population Context

UHL is the primary acute Trust serving the diverse local population of Leicester, Leicestershire and Rutland (LLR); equating to approximately 1.04 million residents, distributed as follows:

Figure 1 Leicester Region



- ▶ Leicester City – population 337,653
- ▶ Leicestershire County – population 667,905
- ▶ Rutland – population 38,022

The City of Leicester is much more ethnically diverse than the county areas.

The overall population is forecast to grow by around 32,000 (3%) by 2019 - a rate of growth slightly lower than that for England as a whole.

The City of Leicester has a relatively younger population than the County areas and this difference will continue to 2019.

## 2.4.2 UHL's Clinical Management

The Trust's Clinical Management is structured into seven management groups, with each group led by a Senior Consultant in the role of Director. The seven Clinical Management Groups (CMGs) are as follows:

- ▶ **CHUGS** Cancer, Haematology, GI Medicine and Surgery
- ▶ **ESM** Emergency and Specialist Medicine
- ▶ **CSI** Clinical Supporting & Imaging
- ▶ **ITAPS** Critical Care, Theatres, Anaesthesia, Pain and Sleep
- ▶ **MSK** Musculoskeletal and Specialist Surgery
- ▶ **RRCV** Renal, Respiratory, Cardiac and Vascular
- ▶ **W&C** Women's and Children's

## 2.4.3 Activity & Finance

The Trust was formed in April 2000 and achieved its financial targets for the first 12 years. Financial results for 2011/12 and 2012/13 show that the Trust made a surplus of £88k and £91k respectively. However 2013/14 was a challenging year both operationally and financially and the Trust reported a deficit for the first time since the organisation was formed. In 2014/15 there was a £40.6 million deficit against a plan of £40.7 million.

UHL provides hospital and community based healthcare services to patients across Leicester, Leicestershire and Rutland and specialist services to patients throughout the UK. As such, the main sources of income are derived from Clinical Commissioning Groups, NHS England, and education and training levies. The Trust are actively engaged with key stakeholders to implement NHS policy to improve health services in the local area through a range of formal and informal partnerships.

### Financial review for the year ended 31 March 2015

UHL did not meet all of its financial and performance duties for 2014/15; as it failed to breakeven. This was, however, in line with our deficit reduction plan. In respect of our duties:

- ▶ **Balancing the books** - delivery of an income and expenditure deficit of £40.6m
- ▶ **Managing cash** - we delivered both the External Financing Limit (EFL) and Capital Resource Limit (CRL)
- ▶ **Investment in buildings, equipment and technology** - invested £46.2 million in capital developments.

## 2.5 The Glenfield Hospital Site

Glenfield Hospital provides a range of medical and surgical services and forms part of the UHL Trust. It is located on the north-western edge of the city centre. The site is located close to the M1 and next to the A50, which is one of the main routes into Leicester providing easy access to main bus routes that serve the wider city. A hopper bus service is also available to and from the site and runs at regular intervals.

## 2.6 Background to the Redevelopment Requirement

Services for Vascular disease cover the provision of surgical, radiological and medical care to patients with circulatory (arterial and venous) disorders. They are categorised as having a high proportion of out-of-hours emergency work<sup>8</sup>.

The Vascular Surgery Unit at UHL currently serves a population of around 1 million, and has an excellent national and international reputation in the clinical management of aneurismal and carotid disease. However it faces several challenges including changes to the vascular trainee allocation and an ageing Consultant workforce. The service is intrinsically linked with the Vascular Surgery Group of the Department of Cardiovascular Sciences at University of Leicester, a group with an international reputation for excellence in both clinical and laboratory research, having both participated in, and led, several key landmark studies in vascular surgery. The vascular unit has been at the top of the national league tables of clinical results in aneurysm and carotid surgical outcomes for many years. The National Vascular Registry 2013 Report on Surgical Outcomes (Consultant Level statistics) notes an average mortality rate for Aortic Aneurysm patients at UHL of 0.4% compared to the national average of 2.4%.

The Vascular Surgical Unit at LRI is a prospering service, with an international reputation as a leader in the field. The current service provides general and complex vascular and endovascular treatments supported by a growing interventional radiology team, specialist nursing, designated ward, vascular scientists and a designated theatre team. The unit hosts regular multidisciplinary (MDT) meetings and has links with cardiothoracic surgery. However such links are made difficult by the separation between two sites; particularly as 40% of vascular surgery is urgent / emergency.

Historically whilst cardiologists and cardiothoracic surgeons have worked closely together at UHL, interventional cardiology procedures and open heart surgery have been undertaken in separate facilities. Interventional cardiology requires advanced imaging capabilities using X-ray fluoroscopy and ultrasound whereas open heart surgery is performed in a traditional theatre setting. However recent innovations have required surgeons and cardiologists to work closely together in the same setting. This requirement is exemplified by the modern approaches to structural heart disease where new devices are enabling minimally invasive approaches to be used to treat conditions which previously required open heart surgery with cardiopulmonary bypass. These 'keyhole' techniques are already producing demonstrable improvements in outcomes

---

<sup>8</sup> SSNDS Definition No.30 Specialised Services for Vascular Disease (adult) (3rd edition)



(both symptoms and mortality) for patients who would be traditionally regarded as inoperable and are also generally associated with shorter lengths of hospital stay and more rapid recovery than open heart surgery.

## 2.7 Existing Arrangements

2.2

2.3

2.4

2.5

2.6

2.7

2.8

At present there is no peripheral angiography service at Glenfield Hospital. There are two Angiography imaging rooms at LRI and the intention is to transfer the activity from one of those rooms to the new Angiography Suite at GH. The advanced imaging capabilities that this service will provide will enhance the patient care that can be offered by Vascular Services. The vacated Angiography room at LRI provides the opportunity to enhance access for other imaging services at LRI subject to a separate business case.

## 2.8 Strategy

This business case, and the associated corporate and project objectives, are supported by a number of significant strategic documents and programmes. This section provides an overview of the driving policies and guidance documents at National, Regional and Local level that can provide context and support the case for change in relation to increasing capacity and providing modern, accessible vascular services. These range from national and local strategies and programmes, to national and local standards and guidance.

### 2.8.1 National Strategies, Programmes and Guidance

Key national strategies, programmes and policies relevant to this project are summarised in the table below.

*Table 5 Strategic Guidance*

National	
Health and Social Care Act 2012	The government's Health and Social Care Bill outlines the future commissioning arrangements across the NHS

National											
NHS Operating Framework	<p>The Operating Framework for the NHS in England 2012/13 sets out the business and planning arrangements for the NHS. It sets out five high level outcome domains that the NHS should be aiming to improve (below). This business case delivers improvements against each domain:</p> <table border="1"> <tr> <td>Domain 1</td> <td>Preventing people from dying prematurely;</td> </tr> <tr> <td>Domain 2</td> <td>Enhancing quality of life for people with long-term conditions;</td> </tr> <tr> <td>Domain 3</td> <td>Helping people to recover from episodes of ill health or following injury;</td> </tr> <tr> <td>Domain 4</td> <td>Ensuring that people have a positive experience of care; and</td> </tr> <tr> <td>Domain 5</td> <td>Treating and caring for people in a safe environment; and protecting them from avoidable harm</td> </tr> </table>	Domain 1	Preventing people from dying prematurely;	Domain 2	Enhancing quality of life for people with long-term conditions;	Domain 3	Helping people to recover from episodes of ill health or following injury;	Domain 4	Ensuring that people have a positive experience of care; and	Domain 5	Treating and caring for people in a safe environment; and protecting them from avoidable harm
Domain 1	Preventing people from dying prematurely;										
Domain 2	Enhancing quality of life for people with long-term conditions;										
Domain 3	Helping people to recover from episodes of ill health or following injury;										
Domain 4	Ensuring that people have a positive experience of care; and										
Domain 5	Treating and caring for people in a safe environment; and protecting them from avoidable harm										
Quality, Innovation, Productivity and Prevention (QIPP)	<p>Within the national context of no significant growth in the NHS forecast, and a requirement to save £20bn by 2015, the Quality, Innovation, Productivity and Prevention (QIPP) is a national initiative looking to provide an integrated, systematic approach to large-scale change. Within this all NHS organisations are encouraged to make better use of existing resources and teams to deliver service improvements. The funding of a new hybrid theatre could secure the future of cardiac services in Leicester, Leicestershire and Rutland in accordance with these principles.</p>										
National Programmes of Care & Clinical Reference Groups	<p><a href="http://www.england.nhs.uk/ourwork/commissioning/spec-services/npc-crg/group-a/a04/">http://www.england.nhs.uk/ourwork/commissioning/spec-services/npc-crg/group-a/a04/</a></p> <p>NHS England is working with a range of stakeholders at a national level to determine the outcomes expected for specialised services. This will be achieved through the development of clinical strategies set out within five national Programmes of Care (PoC) which group together the prescribed (nationally agreed range of) specialised services. These strategies will enable the commissioning of services to be based on clear evidence and ensure that they are cost effective and patient focused. Vascular Services sits within the Internal Medicine PoC.</p>										
2013/14 NHS Standard Contract for Specialised Vascular Services (Adults)	<p>This document sets out the required service standards for vascular services. The most significant are:-</p> <ul style="list-style-type: none"> <li>◆ NHS Abdominal Aortic Aneurysm Screening Programme Guidance for Public Health &amp; Commissioners, July 2009.</li> <li>◆ Royal College of Radiologists – Setting the Standards of Providing a 24 hour Interventional Radiology service, September 2008.</li> <li>◆ Royal College of Radiologists – Standards in Vascular Radiology, 2011</li> <li>◆ NCEPOD Report 2005 – Abdominal Aortic Aneurysm – A service in need of surgery.</li> <li>◆ VSGBI &amp; Royal College of Surgeons – Training in Vascular Surgery &amp; Standards for Vascular Training, 2011</li> <li>◆ Medicines &amp; Health Products Regulatory Agency (MHRA) Joint Working Group to produce guidance on delivering the Endovascular Aneurysm Repair (EVAR) Service (RCR, BSIR, VSGBI, Vascular Anaesthesia Society of Great Britain and Ireland (VASGBI), MHRA</li> </ul>										

National	
	Committee on the Safety of Devices), December 2010
VSGBI: The Provision of Services for Patients with Vascular Disease, 2012.	The 'Provision of Services for Patients with Vascular Disease (2012)' states that almost 50% of patients with vascular disease present as an emergency and that they should expect to access a specialist vascular team incorporating: surgeons; radiologists; anaesthetists; clinical vascular scientists; specialist nurses and therapy staff. This document sets out the requirement for patients to have 24/7 access to specialist vascular care 'locally', recognising that patients may need to travel beyond their local hospital to receive this care.
Interventional Radiology: Guidance for Service Delivery (2010)	This guidance recognises that all acute hospitals should have access to IR services 24 hours a day, every day because an "...effective, well resourced IR service can contribute to significant efficiencies (financial and non-financial) in care pathways in both planned and emergency care."
HBN / HTM Guidance	Health Building Notes (HBN) and Health Technical Memoranda (HTM) provide best practice guidance from the Department of Health. Each area of this project refers to the relevant guidance to inform patient flow and outline design concepts, including (but not limited to): HBN 04-01 Adult Inpatient Accommodation HBN 06 Radiology HBN 26 Theatres

## 2.8.2 Regional Strategy / Guidance

### Joint Strategic Needs Assessment (JSNA)

A Joint Strategic Needs Assessment (JSNA) is a statutory requirement (Health & Social Care Act 2012) placed upon the Directors of Public Health, Adult and Children's Services in all local authorities to guide the commissioning of local health, well-being and social care services. The JSNA provides a systematic method for reviewing the short and long term health and well-being needs of a local population.

The JSNA for Leicester (2012) states that:

"People in the city die early, particularly from circulatory diseases, cancers and respiratory disease. Poor health is largely driven by deprivation and exacerbated by lifestyle factors embedded within communities. The inequalities gap in health between Leicester and England is not narrowing and the gap between the more deprived and the more affluent communities within Leicester has remained a stubborn inequality. We want to improve the health and wellbeing of the poorest fastest."

Leicester is ranked 25th worst out of 326 local authority areas in England on the national Index of Deprivation (2010). There are also areas of deprivation outside the city – notably certain wards of North West Leicestershire.

In general, the next 20 years is forecast to see an increasingly ageing population, particularly in the county areas. Of the total population growth of 32,000 to 2019, 22,000 will be in the over-65 group. This is largely a challenge in the county areas. By contrast, the key challenge in Leicester City will continue to be premature preventable death and disability.

As people grow older, there is a higher preponderance of long term illness and disability. The number of people living with long term conditions will grow as a population ages. Furthermore, many people will have multiple conditions, meaning their care needs are more complex. From a health need perspective there is a marked variation in life expectancy across LLR with the main factors contributing to mortality being cardio-vascular disease (CVD) and respiratory. Any plans for service improvement must respond to these challenges and make a significant contribution towards better outcomes.

This re-emphasises the importance of the JSNA as the starting point for strategy development and commissioning decisions.

### National / Regional Cardiovascular Service Designation Review

The UHL Leicester Vascular Unit is currently designated as a Level 1 Centre (a major vascular service offering all arterial procedures including complex cases). This was as a consequence of the last East Midlands Cardiovascular Network safety, sustainability and accessibility review,

As part of the new specialised commissioning structures these designations are being reviewed. The process for national re-designation of vascular services began in April 2013. It is anticipated that the review will only designate and commission one centre in the East Midlands to provide complex vascular services. UHL aims to be re-designated as the level 1 centre for the East Midlands.

NHS England's standard contract for Specialist Vascular Services sets the following rationale and national strategic direction for vascular services *"to have specialised services for vascular disease concentrated in relatively few specialist centres in order to maximise the use of scarce and expert staff available on a 24 hour a day basis"*<sup>9</sup>. These specialist centres require co-located services including Intensive Care and Interventional Vascular Radiology. In addition it advocates co-location of a number of interdependent services including Interventional Cardiology, Cardiac surgery and Thoracic Surgery.

Meeting all of these requirements provides a key driver for future development of UHLs Vascular service and underpins the project subject of this business case.

---


<sup>9</sup> SSNDS Definition No.30 Specialised Services for Vascular Disease (adult) (3rd edition)

### 2.8.3 A Blueprint for Health & Social Care in LLR: Better Care Together 2014 - 2019

UHL is a key partner in developing the Better Care Together (BCT) programme. BCT represents a partnership of NHS organisations and local authorities across LLR, working together to transform the current and future delivery of services and ensure they are of the highest quality and capable of meeting the future needs of local communities.

The BCT case for change is summarised in the diagram below:

Figure 2 Better Care Together Case for Change



## LLR Health Community Estate

Over the last three years the LLR Health Community has worked together to better understand the collective capacity and estate challenge facing local organisations. Informed by jointly commissioned analysis, the local health community has committed to a strategy to simplify, standardise and share the delivery of core Estates/ FM services and to work together in reducing the collective asset base, better utilise the residual space and capacity footprint and improve the quality of the physical environment.

### 2.8.4 Trust Vision

In the next five years, UHL will become a Trust that is internationally renowned for placing quality, safety and innovation at the centre of service provision. The Trust will build on its strengths in specialised services, research and teaching; offer faster access to high quality care, develop our staff and improve patient experience. The Trust calls this 'Caring at its Best'.

The Trust recognises the challenges facing the organisation and the LLR health and social care system which are the consequence of significant internal and external challenges which include:

- ▶ The financial pressures facing public sector organisations
- ▶ Rigorous regulation of healthcare providers
- ▶ Changes in the wider health and political landscape
- ▶ Focus on choice and greater patient and community involvement
- ▶ Inherent inefficiency of current configuration
- ▶ Fiscal drag of aging estate reflecting incremental development

## 2.8.5 Strategic Objectives

Underpinning the vision and purpose are the strategic objectives of the Trust, these are to provide:

- ▶ Safe, high quality, patient centred healthcare
- ▶ An effective and integrated emergency care system
- ▶ Services which consistently meet national access standards
- ▶ Integrated care in partnership with others (local and specialised)
- ▶ Enhanced delivery in research, innovation and clinical education
- ▶ A caring, professional and engaged workforce
- ▶ A clinically sustainable configuration of services, operating from excellent facilities
- ▶ A financially sustainable NHS organisation
- ▶ Enabled by excellent IM&T

Figure 3 Trust Strategic Objectives

To continue our journey towards delivering Caring at its Best by:

- Reducing avoidable patient deaths and harm and improving patient experience, through the next phase of our Quality Commitment
- Raising levels of staff engagement by accelerating the spread of Listening into Action and improved leadership at all levels
- Starting our £320m investment programme (with the Emergency Floor) and introducing new models of care under Better Care Together
- Making further improvements to our emergency care system and hitting key patient access standards



By delivering the strategic vision the Trust will fulfil the purpose of providing 'Caring at its Best'.

## 2.8.6 Caring at its Best

The UHL team is made up of more than 10,000 staff providing a range of services primarily for the one million residents of Leicester, Leicestershire and Rutland. The nationally and internationally-renowned specialist treatment and services in cardio-respiratory diseases, cancer and renal disorders reach a further two to three million patients from the rest of the country.

UHL work with partners at the University of Leicester and De Montfort University providing world-class teaching to nurture and develop the next generation of doctors, nurses and other healthcare professionals, many of whom go on to spend their working lives with the Trust.

The Trust focuses on being at the forefront of many research programmes and new surgical procedures, in areas such as diabetes, genetics, cancer and cardio-respiratory diseases. UHL is now the home of three National Institute of Health Research (NIHR) Biomedical Research Units and during the year carried out over 800 clinical trials, bringing further benefits to thousands of patients.

The heart centre at the Glenfield Hospital continues to lead the way in developing new and innovative research and techniques, TAVI (Trans-Catheter Aortic Valve Insertion) and the use of the suture-less valves in heart surgery. UHL also have one of the best vascular services nationally, with more patients surviving longer after following an aneurysm repair (to fix a life threatening bulge in a blood vessel).

The Trust is proud to have some of the lowest rates of hospital-acquired infections, such as C. Difficile and MRSA, in the country; the hospital standardised mortality rates are very good, demonstrating a high clinical quality; with the provision of food also been rated as 'excellent' by an independent panel.

UHL's purpose is to provide 'Caring at its Best' and staff have helped to create a set of values, which are:

Figure 4 *Caring at its Best*





UHL patients are at the heart of all that is done at the Trust. 'Caring at its Best' is not just about the treatments and services provided but about giving patients the best possible experience.

Each element of the objectives and supporting strategy are performance managed through the Trust Board scorecard, regularly reported to Board through the Integrated Performance Report (IPR).

## 2.8.7 Clinical Strategy

The Trust's clinical strategy is focused on delivering high-quality, patient centred services in the most appropriate setting with excellent clinical outcomes. There will be a process of continual quality improvement for clinical outcomes, morbidity and mortality rates and other clinical indicators to ensure that the Trust remain the provider of choice for patients.

### ▶ Developing a more flexible and integrated workforce

The model of clinical practice will be to provide consultant delivered, rather than consultant led, patient care. It will create a sustainable workforce for the delivery of responsive multi-disciplinary clinical services 7 days a week which meets the needs of patients and clinicians. It will seek and exploit opportunities for service integration across health and social care by removing the historical barriers to change. Training and education will play an integral part in ensuring staff have the right skills now and for the future. Training opportunities to support self-care in long-term condition management and carers will be explored.

The strategy reflects the changes in population demographics, placing the patient at the centre of service planning and design ensuring that holistic patient centred care remains at the heart of everything we do. For example services will be tailored to meet the challenges of a rising elderly population; ensuring integrated care is provided across primary, community and social care. The Trust will work with partners to develop the infrastructure and networks to offer expertise across the health community to ensure that care for the older person is as seamless as possible.

### ▶ Consolidating and making better use of finite resource

People are living longer, and the NHS' ability to treat and help to manage conditions that were previously life-threatening continues to improve. Alongside this, the NHS faces a potential funding gap of around £30 billion by 2020/21 meaning that the NHS will need to radically transform the way it has traditionally provided care to new and innovative models necessitating a significant shift in activity and resource from the hospital sector to the community.

UHL will meet this funding gap by working collaboratively with its LLR Health & Social Care partners to re-design patient care pathways to ensure that they continue to provide high quality care, outcomes and patient experience whilst delivering value for money. The Trust has an on-going operating deficit in part related to the current configuration of its clinical services which do not optimise clinical adjacencies and patient pathways. In order to deliver financially sustainable, high quality services in the future, UHL's hospitals will need to become smaller and more specialised whilst supporting delivery of care in the

community. As a consequence UHL has developed a clinical and estates strategy that optimises where and on which site its services are located as care pathways are changed to meet the financial challenge. The methodology about future location of services is clinically driven, evidence based, inclusive, open and transparent, and involve patients and the public in a meaningful way however will necessitate tough decisions for the health community if it is to meet the 'value for money' test.

The Trust are proactively responding to the national drive towards fewer regional centres of excellence for specialised services by ensuring its services deliver innovative, high quality patient care through robust Research & Development programmes which enable patients to benefit from leading edge developments in the care of specific conditions.

The Trust will specifically seek to ensure it remains as a national centre of excellence for its work in Cardiac, Respiratory, Vascular, Renal, Cancer and Diabetes and significantly strengthen its portfolio of other key services to ensure they are sustainable in the future.

## 2.8.8 Trust Five Year Integrated Business Plan 2014 – 2019

The five year strategy was developed through four key phases: evidence gathering; analysis, synthesis and planning. In developing the strategy the Trust identified that it operated predominantly in two core markets:

- ▶ Local services for LLR where it is the major provider of local secondary care services
- ▶ The wider Midlands and East regional economy where the Trust is a key provider of specialised adult and children's services

## 2.8.9 Trust's Five Year Estate Strategy June 2014

The Trust has undertaken an exercise to review the strategic future of its estate, with a view to creating a development control plan that looks twenty years ahead. "The quality and fitness for purpose of the NHS Estate and the services that maintain it are integral to delivering high quality, safe and efficient care"<sup>10</sup>. It is also an area of significant spend; the budget for Estates and FM Services across the Trust in 2013/14 was £31m.

The Trust's estate strategy identifies the need for flexibility to move property from being a constraint to an enabler for change. UHL is developing a Hospitals Estate Transformation Plan which is based on a strategy that consolidates the estate, develops new facilities, disposes of surplus land and buildings and encourages third party partnerships that will raise income for the Trust. This will be a cornerstone of service reconfiguration and improved utilisation of the Trust's estate. This must be balanced by organisational and public expectations about the provision of highly specialised services alongside local access to primary and secondary care, in the

---

<sup>10</sup>Treasury Value for Money Update, 2009

context of high levels of public support for the associated hospitals. It is in this context that the opportunity for significant and far reaching estate transformation will be determined.

The Transformation Plan will;

- ▶ Underpin the strategic direction
- ▶ Support the clinical strategy to improve patient pathways and improve quality of care
- ▶ Support the strategic outline case for the whole site reconfiguration
- ▶ Show a clear implementation programme over five years for transformation with tangible benefits
- ▶ Improve the patient and staff built environment, investing in improved facilities and infrastructure; greatly aiding recruitment and retention
- ▶ Identify capital development to unlock the embedded value of Trust assets and support its ability to deliver clinical transformation and achieve QIPP efficiency savings

Efficient estate solutions will improve frontline service provision as well as achieving improved utilisation of the estate and unlocking its embedded value. This is possible by delivering a high quality clinical and working environment for patients and staff, resulting in better levels of productivity, flexibility and patient satisfaction. This will also support cross-CMG strategies that maximise optimisation of the estate resources across UHL. This strategy is relevant to this business case; the Estates Transformation Plan will set out detailed strategies for its three main hospital sites.

The Estates Strategy will be updated during 2015/16.

## 2.9 Summary

The development of an Angiography Suite as part of the transfer of vascular services from LRI to GH is fully aligned with the national, regional and corporate strategies and policies. The co-location with other specialised services at Glenfield Hospital will ensure that safe, high quality patient-centred healthcare can be delivered to the population of Leicester, Leicestershire and Rutland.

In addition the creation of an Angiography & VSU supports the following Trust aims and objectives:

- ▶ Safe, high quality, patient centred healthcare
- ▶ Services which consistently meet national access standards
- ▶ Integrated care in partnership with others (local and specialised)
- ▶ Enhanced delivery in research, innovation and clinical education
- ▶ A caring, professional and engaged workforce

- ▶ A clinically sustainable configuration of services, operating from excellent facilities
- ▶ A financially sustainable NHS organisation
- ▶ Enabled by excellent IM&T

A corporate decision has been made to progress this project at pace as an enabler to the ICU project. Independently it still sits within the reconfiguration programme.

The Angiography Suite & VSU transfer is key in supporting the Trust's Five year plan and service strategies for the future, by increasing specialist services on the GH site and by releasing theatre capacity at the LRI. In the context of national, regional and Trust strategies, it is recognised that investment is required to achieve the project objectives. The proposals detailed in this FBC provide a flexible solution that will enable the Trust to achieve these aims.

## Part B: The Case for Change

### 2.10 Introduction

The purpose of this section of the business case is to outline the strategic case for change.

### 2.11 Clinical Drivers for Change

- ▶ To continue to safely provide the best care for the most critically ill patients
- ▶ To meet increasing demand for vascular services which is greater than the current capacity can provide. Historic trends in growth suggest a 5% annual growth in vascular services
- ▶ Requirement for single site vascular and cardio-thoracic departments that incorporates key adjacencies and presence of diagnostics and medical assessment services. This enables implementation of the developed model of care for adults accessing this service
- ▶ Changes in the local and national demographics combined with the Trust's plan to develop a level 1 Vascular Centre for Leicester is impacting on increased demand
- ▶ Redevelopment and increased capacity will provide opportunities for the Trust to fulfil its strategic redevelopment programme

2.9

2.10

2.11

2.12

### 2.12 Current Activity & Demand

2.13

The Vascular Angiography Business case is predicated that there will be an increase in demand when UHL becomes a designated level 1 vascular centre. Discussions are at a developed stage to undertake complex vascular work from Northampton and Lincoln.

## 2.13 Constraints and Dependencies

The constraints and dependencies relevant to the project are:

- ▶ **Budget** – the Trust has made provision to fund this scheme from its capital programme over two financial years (2014/15 + 2015/16)
- ▶ **Physical** – the works will be taking place adjacent to a live clinical environment with limited access internally. The construction access to the proposed angiography suite are constrained due to adjacency to 'live' clinical areas
- ▶ **Timescales** – to continue to develop and support Vascular and cardiac services, the expectation is that the angiography suite will be delivered by April 2016.
- ▶ **Retained Estate** – the use of existing retained estate for the development creates design compromises and derogations from HBN guidance due to the physical site constraints
- ▶ **Infrastructure** – any development of GH site is contingent upon the required estate infrastructure to support developments. A site-wide infrastructure review has been commissioned by the Trust and Glenfield Hospital has been the first site surveyed.
- ▶ **Trust Transformation Programme** – Trust wide schemes for redevelopment of the Trust sites are all interdependent. It is essential that phasing and enabling works are scoped accurately to minimise any disruption.

## 2.14 Stakeholder Engagement

During July / August 2013 a public engagement / consultation exercise was undertaken with both patients and members of staff to assess support for the Trust's plans for a single site take for General Surgery. In addition there were specific questions relating to the vascular services transfer. Both paper and online surveys were undertaken. The results are indicated below, with further detail in Appendix 1.

Table 6 Patient Survey Response

	Question	Total	Yes	No	Blanks	Yes%	No%
Paper	Do you support our plans to develop Vascular Services with a new Hybrid Operating Theatre inpatient ward and Angiography suite	49	43	3	3	93%	7%
Paper	Do you support the plans to bring together our Vascular, Cardiac and Thoracic teams to improve the outcomes of our patients?	49	44	3	2	94%	6%

Paper	If the Vascular Service was moved to the Glenfield Hospital to provide better outcomes for our patients would it provide you as a patient with any problems	49	9	26	14	26%	74%
-------	---	----	---	----	----	-----	-----

Further stakeholder engagement has been undertaken as part of the development of the Full Business Case, supported by the Communications Department.


## 2.14

### 2.14.1 UHL Quality Commitment

UHL are committed to improving the quality and safety of care for patients. The quality commitment articulates 3 key aims:

- ▶ Provide Effective Care – Improve Patient Outcomes. “To deliver evidence based care/best practice and effective pathways and to improve clinician and patient reported outcomes”
- ▶ Improve Safety – Reduce Harm. “To reduce avoidable death and injury , to improve patient safety culture and leadership and to reduce the risk of error and adverse incidents”
- ▶ Care and Compassion – Improve Patient Experience. “To listen and learn from patient feedback and to improve patient experience of care”

Figure 5 UHL's Quality Commitment



This case has been developed with a view to enhancing delivery of the quality of care by:

- ▶ Improving patient pathway management reducing the clinical risk and discomfort through the emergency care pathway
- ▶ Improving the patient experience
- ▶ Enhancing Patient safety and reducing clinical risk

As a consequence a Due Regard / Quality Impact Assessment has been undertaken to ensure that these commitments are recognised as part of the development, which can be found at Appendix 2.

## 2.15 Investment Objectives, Key Deliverables & Benefits Criteria

In the context of the above and the Trust's Corporate objectives outlined in Section 2.9, the 'SMART' investment objectives for this project are detailed below as part of the



wider Benefit's Realisation Plan, clearly outlining what the scheme is set to achieve and how.

It is important to note that agreement of the following from the Project Board, Steering Group and wider stakeholder group, informed the Qualitative Benefits Appraisal detailed in the Economic Case.

Table 7 Investment Objectives & Wider Benefits Realisation Plan

Investment Objective	Project Objective	Benefit	Enablers	Outcome	Baseline Measure	Target date	Owner
A. Business Need	1. To develop a centre of excellence, enhancing the Trust's reputation for training, service delivery and treatment, through the provision of a centralised service in modern accommodation.	Support and consolidate the provision of cardio-vascular services on one site	<ul style="list-style-type: none"> <li>Robust Design process</li> <li>Engagement of stakeholders</li> <li>Key internal adjacencies compliant with Strategic guidance</li> </ul>	<ul style="list-style-type: none"> <li>Reconfiguration will allow vascular &amp; cardio-vascular services to be co-located providing a new pathway for treatment</li> <li>Clinically appropriate treatment in centre of excellence (critical mass and centralisation of service)</li> </ul>	<ul style="list-style-type: none"> <li>Vascular &amp; Cardio-vascular Departments is on one single site</li> <li>Stakeholders agree and sign off on design</li> <li>Surgery and radiological follow-up are implemented as key adjacencies</li> </ul>	Completed in December 2016 as final part of vascular relocation	Project Board
	2. To increase the productivity of surgical vascular & cardio-thoracic care at Glenfield	Improve patient pathway management reducing the clinical risk and discomfort through the surgical care pathway	<ul style="list-style-type: none"> <li>Patient information</li> <li>Improved patient pathway</li> <li>Trust KPI targets</li> </ul>	<ul style="list-style-type: none"> <li>Clinically appropriate transfer of patients</li> <li>Reduced LOS as a result of 'one stop' procedures</li> <li>KPI targets meet</li> </ul>	<ul style="list-style-type: none"> <li>PLACE surveys and complaints register</li> <li>Trust risk register</li> </ul>	December 2016	CMG
B. Strategic Fit	3. To ensure that the changing needs and expectations of a growing population are met in line with Trust clinical strategy and national guidance standards	Ensures that the service model of care is delivered in line with National, Trust and local health economy KPIs	<ul style="list-style-type: none"> <li>Compliance to best practice standards and national and local KPIs</li> </ul>	<ul style="list-style-type: none"> <li>Improved patient experience</li> </ul>	<ul style="list-style-type: none"> <li>Patient survey (PLACE)</li> <li>Current quarterly performance reports</li> </ul>	Patient survey has to be carried out prior to implementation of new service	CMG
C. Quality	4. To improve the clinical effectiveness and safety of vascular & cardio-vascular service across Leicester	Quality of care is enhanced, in terms of the model of care, and seamless pathways of care and patient flows.	<ul style="list-style-type: none"> <li>Model of care and design enhance efficiencies in reducing number of separate procedures and LOS</li> </ul>	<ul style="list-style-type: none"> <li>Acute and elective pathways reflecting best practice</li> <li>Reduced LOS</li> </ul>	<ul style="list-style-type: none"> <li>Current data</li> <li>Quality indicators report</li> <li>Quarterly performance reports</li> </ul>	December 2016	CMG
		The built environment enhances clinical practice that support clinical effectiveness, improved patient outcomes and patient safety	<ul style="list-style-type: none"> <li>Robust Design process</li> <li>Engagement of stakeholders</li> <li>Key internal adjacencies compliant with Strategic guidance</li> </ul>	<ul style="list-style-type: none"> <li>KPI figures reflect current benchmark relating to patient safety, referral, diagnosis and treatment time</li> </ul>	<ul style="list-style-type: none"> <li>PLACE surveys and complaints register</li> <li>Staff surveys</li> <li>2012/13 Quality indicators</li> <li>2012/14 performance reports</li> </ul>	December 2016	Project Board
	5. To improve the clinical adjacencies of services to optimise clinical safety and reduce clinical risk.	Provides enhanced departmental relationships and clinical adjacencies that support clinical effectiveness and improved patient outcomes	<ul style="list-style-type: none"> <li>Key internal adjacencies compliant with Strategic guidance</li> </ul>	<ul style="list-style-type: none"> <li>Centralisation of vascular &amp; cardio-vascular surgery ensuring:</li> <li>Patient focused pathways with more rapid and increased access to specialist care</li> </ul>	<ul style="list-style-type: none"> <li>2012/13 Quality indicators</li> <li>2012/14 performance reports</li> <li>Staff surveys</li> </ul>	December 2016	Project Board
D. Sustainability, Service Modernisation, Value for Money	6. To equip the angiography suite to respond effectively to existing and known commissioning requirements, as well as to respond flexibly to future changes in service direction and demand.	Improved patient flow for 'one stop' procedures. Flexible use of angiography space	<ul style="list-style-type: none"> <li>Design provides seamless surgical facility for cardio-thoracic procedures</li> </ul>	<ul style="list-style-type: none"> <li>PLACE scores / audits will reflect positive patient feedback</li> </ul>	<ul style="list-style-type: none"> <li>PLACE surveys</li> </ul>	December 2016	CMG

Investment Objective	Project Objective	Benefit	Enablers	Outcome	Baseline Measure	Target date	Owner
	7. To create a design which is fit for purpose	Improved Privacy and dignity provisions for all patients	<ul style="list-style-type: none"> <li>• Design provides an appropriate caring environment to facilitate the best care for patients</li> </ul>	<ul style="list-style-type: none"> <li>• PLACE scores / audits will reflect positive patient feedback</li> </ul>	<ul style="list-style-type: none"> <li>• PLACE surveys</li> </ul>	Summer 2017	CMG
		Consolidates existing services & provides clinical expertise	<ul style="list-style-type: none"> <li>• Specialist theatre and radiology staff (existing and new) to be recruited to staff facility</li> </ul>	<ul style="list-style-type: none"> <li>• Reconfiguration will allow cardio-thoracic / vascular to be co-located providing an enhanced pathways for assessment and treatment</li> </ul>	<ul style="list-style-type: none"> <li>• PLACE surveys and complaints register</li> <li>• Trust risk register</li> <li>• Staff surveys</li> <li>• 2012/13 Quality indicators</li> <li>• 2012/14 performance reports</li> </ul>	Summer 2017	Project Board
E. Meeting Commissioners' intentions for healthcare services	8. The development will be delivered on time with minimal disruption to current service delivery	The enabling moves will facilitate the Vascular and ICU programme whilst minimising delay to delivery	<ul style="list-style-type: none"> <li>• OBC and FBC approval</li> <li>• Planning approval</li> <li>• Efficient programme management</li> <li>• Robust Design process</li> <li>• Engagement of stakeholders</li> </ul>	<ul style="list-style-type: none"> <li>• Post Project Evaluation highlights project is completed on time and Vascular services provided with minimal disruption</li> </ul>	<ul style="list-style-type: none"> <li>• Programme plan</li> </ul>	Summer 2017	Project Board
		Reduces complexity and sequence dependency of enabling moves	<ul style="list-style-type: none"> <li>• OBC and FBC approval</li> <li>• Planning approval</li> <li>• Efficient programme management</li> <li>• Robust Design process</li> <li>• Engagement of stakeholders</li> </ul>	<ul style="list-style-type: none"> <li>• Design process and programme plan implemented that utilised a solution with minimal complexity and dependency on enabling works/moves</li> </ul>	<ul style="list-style-type: none"> <li>• Programme plan</li> </ul>	Summer 2017	Project Board

## 2.16 Benefits Realisation

Work has been undertaken by the Trust to identify and quantify the clinical benefits resulting from this project. These include:

- ▶ **Strategic Fit:** in keeping with the longer term site reconfiguration proposals, acting as an enabler to other service moves and relocation. Enables the co-location of services that supports evidence based practice, innovation in developing new models of care and provides a seamless service to adults and children.
- ▶ **Clinical Quality and Patient Safety:** access to senior decision makers, immediate diagnostic support on one site
- ▶ **Patient Outcomes:** reduced harm, improved morbidity and mortality and opportunities for improved clinical outcome.
- ▶ **Patient Experience:** responsive no delays system in a dedicated bespoke environment
- ▶ **Clinical Staff & Resources:** improved patient flow, proximity of services and an environment tailored to meet demand will increase staff satisfaction, improve morale and mitigate stress. Reduced sickness absence levels with higher rates of recruitment and retention as the emergency floor be recommended as a place to come and work. The floor will enable more effective ways of working and reduce duplication of work and facilitate collaborative interdisciplinary working.

## 2.17 Potential Business Scope & Key Service Requirements

The Trust is seeking to improve its vascular Angiography Suite and VSU service through the relocation to the GH site.

The main components of the required scope for the Angiography Suite & VSU are:

- ▶ One Angiography Suite
- ▶ One first stage recovery bed
- ▶ Four second stage recovery
- ▶ Waiting area
- ▶ Diagnostic Imaging via VSU
- ▶ Two diagnostic rooms
- ▶ Reception
- ▶ Waiting area

## 2.18 Summary

The relocation of the angiography suite and VSU to support Vascular Services at Glenfield Hospital frees up capacity at the LRI for the transfer of level 3 critical care and associated clinical services from the LGH.

The move will also help further develop vascular services with cardiology / cardiothoracic services at Glenfield and should reinforce vascular services re-designation as a Level One centre, giving them the ability to continue to attract the complex cases from both around the region and nationally. This combined with the vascular surgeon's outstanding clinical portfolio and results will keep Leicester as one of the country's top centres for this type of surgery. This will bring research and academic recognition and ensure that the reputation of UHL as a centre of excellence is sustained such that UHL continues to retain and attract the best surgeons in the country.

This investment will provide opportunities to safeguard a number of services (as national commissioning continues in earnest) and further develop the range of procedures it can deliver. It will benefit Cardiology and Cardiothoracic Services through access to these facilities, again further developing the range of procedures they can offer and developing closer working practices between the services.

In the context of the national, regional and Trust strategies, it is recognised that investment is required to achieve the project objectives. The proposals outlined in this FBC provide a flexible solution that will enable the Trust to achieve these aims.

## 3 | The Economic Case

### 3.1 Introduction

In accordance with the Capital Investment Manual and requirements of HM Treasury's Green Book (A Guide to Investment Appraisal in the Public Sector), this section of the FBC reaffirms the preferred option highlighted in the OBC. It reviews the changes in capital and revenue costs from the OBC and identifies reasons why the changes have happened and their impact on the position of the preferred option. The OBC, approved by the Trust Board, covered the transfer of the vascular service to the Glenfield Hospital, the development of an angiography suite for vascular patients and the development of a Hybrid theatre to support the expansion of the vascular service.

3

3.1

### 3.2 OBC Options Appraisal

The three short listed options at OBC stage were as follows:

- ▶ **Option A:** Vascular Ward/VSU on Ward 23a, Angiography Suite in vacated TSSD, Hybrid Theatre in new build in courtyard
- ▶ **Option B:** Vascular Ward/VSU on Ward 23a, Angiography Suite in vacated TSSD, Hybrid Theatre in combined theatres 5 & 6
- ▶ **Option C:** Vascular Ward/VSU on Ward 23a, Angiography Suite in vacated TSSD, Hybrid Theatre in converted theatre 9

The OBC financial appraisal can be summarised in the following table:

*Table 8 OBC Economic Appraisal Summary*

Option	Appraisal period	NPC £'000	Risk Adjusted £'000	Risk Adjusted NPC £'000
Do Nothing	60 years	237,892	0	238,272
Option A	60 years	378,437	380	378,817
Option B	60 years	379,701	412	380,113
Option C	60 years	376,714	332	377,046

This was combined with the non-financial scores to provide a combined appraisal, resulting in the following:



Table 9 Combining the OBC Financial and Non-Financial Scores

Option	Option A	Option B	Option C
Weighted Scores	878.9	638.7	649.9
Rank (non-financial)	1	3	2
Net present cost (NPC) (£k)	378,438	379,701	376,715
Rank (VFM)	2	3	1
NPC per point score (£k)	431	594	580
Rank	1	3	2

In conclusion Option A was identified as the preferred option and progressed to the FBC stage.

At the time of the OBC the Do Minimum was not evaluated for a non-financial perspective. This was subsequently carried out on a consistent basis by the same team involved in the original option appraisal. The weighted score for the Do Minimum was 314.5. The Net Present Cost (NPC) per benefit point would therefore have been £756 and the Do Nothing would have been ranked 4<sup>th</sup>.

### 3.2.1 Estimating Costs

The FBC costs have been determined by Interserve and the Trust's Cost Advisors, and are in accordance with NHS standards. The total capital costs for the preferred option at OBC stage and FBC stage are summarised below.

Table 10 Vascular Capital Costs for the Hybrid Theatre, Vascular Ward, Angiography Suite &amp; Vascular Studies Unit at OBC &amp; FBC

Capital Costs	OBC Stage	FBC Stage
	(£)	(£)
Construction	6,007,911	6,434,391
Fees	1,568,256	1,341,404
Non Works Costs	603,200	687,394
Equipment	1,656,298	1,310,586
Planning Contingency	464,023	381,983



Capital Costs	OBC Stage (£)	FBC Stage (£)
Optimism Bias	802,761	368,176
<b>Total for approval purposes</b>	<b>11,102,448</b>	<b>10,523,934</b>
Inflation	845,712	2,664,753
<b>Grand Total</b>	<b>11,948,160</b>	<b>13,188,687</b>

The above analysis shows a reduction in costs at a common price base for approval purposes (PUBSEC 171) of 5.2%. The OBC had assumed a PUBSEC index of 191 to forecast outturn expenditure this has increased to PUBSEC 213.

This FBC reflects the angiography suite and VSU components of the Vascular OBC. The Trust has calculated the split of the overall OBC cost to identify any changes on costs reflecting the angiography suite and VSU development. This is as follows:

Table 11 *Angiography & VSU Capital Costs at OBC & FBC*

Capital Costs Angiography & VSU	OBC Stage (£)	FBC Stage (£)
Construction	1,832,466	2,184,254
Fees	478,332	456,053
Non Works Costs	315,433	335,183
Equipment	161,072	118,158
Planning Contingency	124,216	117,331
Optimism Bias	212,669	113,090
<b>Total for approval purposes</b>	<b>3,124,187</b>	<b>3,324,069</b>
Inflation	238,059	840,833
<b>Grand Total</b>	<b>3,362,246</b>	<b>4,164,902</b>

This reflects a 6.4% increase in the approval sum. Comparing the outturn figures for the total vascular programme and the vascular angiography project, the percentage changes in capital cost are as follows:

Vascular Programme -10.4%

Vascular Angiography & VSU Project – 23.85%

### 3.2.2 Revenue Costs

The revenue changes in the OBC have been reviewed and worked up in more detail. The following table reflects the position at OBC of the preferred option:

*Table 12 OBC Revenue Costs for all Vascular Services*

Revenue cost for GEM	2015 /16 £'000	2016 /17 £'000	2017 /18 £'000	2018 /19 £'000	2019 /20 £'000	2020 /21 £'000
Current Costs (Do Nothing)	11,854	11,854	11,854	11,854	11,854	11,854
Additional staff costs	0	0	825	882	810	570
UHL Other staff	0	0	613	1,226	1,226	1,226
New FM costs	0	0	113	150	150	150
Additional Non Pay	0	0	28	37	37	37
<b>Total Costs</b>	<b>11,854</b>	<b>11,854</b>	<b>13,433</b>	<b>14,149</b>	<b>14,077</b>	<b>13,837</b>

This showed an increase in costs of circa £2.5 million. Some of these costs were transitional and the additional cost was reduced to £2.1 million by 2020/21. A significant element of these costs related to theatres at the LRI, where £1.2 million had been allowed for to reflect the additional cost of running emergency theatres on three sites and the level of fixed costs at the LRI. The additional costs were partially offset by additional income of £368,000 per annum.

The current position for the vascular programme is as follows:

*Table 13 FBC Revenue Costs for all Vascular Services*

Revenue cost for GEM	2015 /16 £'000	2016 /17 £'000	2017 /18 £'000	2018 /19 £'000	2019 /20 £'000	2020 /21 £'000
Current Costs (Do Nothing)	11,854	11,854	11,854	11,854	11,854	11,854
Additional staff costs	0	1,542	1,498	1,498	1,498	1,498
Savings from 2 Site consolidation					(1,255)	(1,255)
New FM costs	0	0	12	48	48	48
Additional Non Pay	0	19	88	184	184	184
<b>Total Costs</b>	<b>11,854</b>	<b>13,414</b>	<b>13,452</b>	<b>13,584</b>	<b>12,774</b>	<b>12,774</b>

Additional costs have been reviewed in the context of the requirement for Angiography and theatres at the Glenfield. The Vascular programme now accounts for the critical care moves required to be implemented to ensure sustainability of the service. Additional income of £187,000 in 2016/17 and £486,000 in 2017/18 has been assumed.

The additional costs for vascular angiography suite and VSU in the OBC have been identified as follows, these allow for an uplift to the baseline to account for the angiography business case:

Table 14 OBC Revenue Costs for Angiography & VSU

Revenue cost for Angiography VSU	2015 /16	2016 /17	2017 /18	2018 /19	2019 /20	2020 /21
	£'000	£'000	£'000	£'000	£'000	£'000
Current Costs (Do Nothing)	11,854	11,854	13,173	13,843	13,771	13,531
Additional staff costs	0	0	19	19	19	19
UHL Other staff	0	0	0	0	0	0
New FM costs	0	0	0	0	0	0
Additional Non Pay	0	0	7	9	9	9
<b>Total Costs</b>	<b>11,854</b>	<b>11,854</b>	<b>13,198</b>	<b>13,870</b>	<b>13,798</b>	<b>13,558</b>
Additional costs of Angiography	0	0	26	28	28	28

This compares to the following FBC position:

Table 15 FBC Revenue Costs for Angiography & VSU

Revenue cost for GEM Angiography & VSU	2015 /16	2016 /17	2017 /18	2018 /19	2019 /20	2020 /21
	£'000	£'000	£'000	£'000	£'000	£'000
Current Costs (Do Nothing)	11,854	13,348	13,236	13,236	11,981	11,981
Additional staff costs	0	22	22	22	22	22
Savings from 2 Site consolidation						0
New FM costs	0	0	0	0	0	0
Additional Non Pay	0	9	21	21	21	21
<b>Total Costs</b>	<b>11,854</b>	<b>13,379</b>	<b>13,279</b>	<b>13,279</b>	<b>12,024</b>	<b>12,024</b>
Additional Cost of Angiography	0	31	43	43	43	43

There is little change in the revenue costs with the exception of timing and an allowance for equipment maintenance The FBC anticipates that the Angiography suite will be operational by April 2016.

### 3.2.3 Summary of FBC Position Compared to OBC

The changes between OBC and FBC are as follows:

Table 16 Changes between OBC and FBC

	OBC £'000	FBC £'000	Comment
<b>Capital Costs – Approval Sum Vascular Programme</b>	11,102	10,523	Equipment at FBC deflated to account for Capital Cost inflation reduction of 5.2%
<b>Capital Costs – Outturn Vascular Programme</b>	11,948	13,188	Capital cost inflation significantly higher than that anticipated at OBC. Increase of 10.4%
<b>Capital Costs Approval Sum Angiography</b>	3,124	3,324	Increase in Approval sum of 6.4%
<b>Capital Costs Outturn Angiography</b>	3,362	4,165	Increase in outturn sum of 23.9%
<b>Annual Revenue Costs (2020/21)</b>	13,558	12,024	Revision of radiology and non-recurrent costs in Vascular Ward business Case. Small increase in angiography costs to reflect equipment maintenance and higher grade VSU staff

### 3.2.4 Compliance with Capital Investment Manual & NTDA Thresholds

Capital costs have increased in respect of the approval sum and outturn. Revenue costs for Angiography are slightly increased to account for equipment maintenance. However the overall costs of the vascular moves have reduced as a result of assuming the saving on non-recurrent costs on consolidation and revision on radiology costs.

Capital costs are significantly greater than the OBC, although the scheme is within the 10% threshold in respect of the approval sum. Although the CIM states that the option appraisal should be reviewed if costs are outside 10% capital or 5% revenue either way, all the options from a revenue perspective would be affected in a similar way. It is also likely that the capital position for each option would be impacted equally; and the next best Option (option 3) would need to reduce revenue costs by over £4 million to become the preferred option at OBC. This saving would then need to be greater in a revised option appraisal. Even if there was no capital expenditure in Option 3 it would still not be the preferred option. On this basis the preferred option at OBC stage still stands.

## 3.3 The Preferred Option

The Angiography Suite will be a 'refurbishment' development of redundant space previously used as a sterile services store at the Glenfield site. The VSU will be located

within the current ward 24 adjacent to the proposed vascular ward to allow timely scanning diagnosis for inpatients as well as providing an outpatient service. As this is internal works there are no planning consent issues. Designs have been reviewed and discussed with a number of key stakeholders to ensure the proposal complies with local policy.

### 3.3.1 Design Solution

The final design solution has been developed from OBC to FBC in conjunction with detailed discussions with key clinical stakeholders at all times from initially developing operational policies, patient flows and clinical models to further refine with the development of a Planning Policy and Design Description document to inform the design solution.

The Trust identified a number of key design principles, which underpinned the development of the design solution.

- ▶ Be fit for purpose
- ▶ Deliver high quality, safe, efficient and effective care
- ▶ Improve patient and staff experience by ensuring patients receive high quality care and service in modern health-care facilities
- ▶ Generic design of facilities to ensure maximum flexibility for future service developments
- ▶ Future proof wherever possible.
- ▶ Conforms to current HBN whenever possible
- ▶ Creates an environment, which respects the needs of all patients in terms of privacy and dignity.

It was recognised that models of service delivery change with time, therefore it is essential that the facilities will respond to the future changes in technology but also changes in clinical support services. From October 2014, the design team worked with clinical stakeholders to further develop the design from 1:200 as described within the OBC, to more detailed 1:20 detail to show functional room layouts. The Angiography and VSU design solution was based upon detailed activity reflecting the transfer of vascular activity to the Glenfield Hospital site and with capacity modelling undertaken as part of the OBC process.

The facility will comprise of:

- ▶ One radiology angiography suite
- ▶ Reception area
- ▶ Pre-assessment area
- ▶ Post procedure recovery (initial) room
- ▶ 6 recovery/day-case beds

The VSU element is planned as a refurbishment of existing accommodation to create:

- ▶ Two ultrasound scanning rooms
- ▶ Reception area/office
- ▶ Waiting room
- ▶ Store facilities

The design solution, including schedule of accommodation and equipment has been reviewed and formally signed-off by all key stakeholders.

Schedules of accommodation and outline 1:20 layouts are described in more detail within the Estates Annex (Appendix 3).

### 3.3.2 Equipment Strategy

The Trust intends to implement an equipment strategy that incorporates the following:

- ▶ Ownership of the majority of equipment (including transfer of significant percentage)
- ▶ Some Equipment leased e.g. beds and trolleys leased under the bed management contract
- ▶ Larger imaging equipment within Angiography will be included within the Trust's managed equipment service contract

The Original Vascular OBC described a transfer of existing Toshiba angiography scanning equipment for the LRI. This equipment is part of an existing MES contract agreement with the design team liaising with Astral to agree a methodology to transfer the equipment when required. This element transfer will be managed under Astral supervision however the cost has been recognised within the capital cost plan.

In addition, the existing supporting angiography equipment will be transferred and the current LRI facility decommissioned thereafter however it was recognised that there will need to be a capital allocation as full transfer is unlikely due to the poor fit with new design solution, difficulty in transferring existing equipment or that equipment is beyond its useful life cycle.

The equipment strategy and equipment schedules were informed and further refined as part of the FBC design development. Detailed design to 1:20 enabled the project team to create room data sheets based on the functional requirement. The room data sheets describe the *standard* equipment required for each room. This has been tabulated and compared against the proposed equipment transfer list. An equipment list for new and transferrable equipment was shared and signed off by clinical teams to ensure that all items were captured. The new equipment schedule has been shared with procurement to apply current market costs to each item. The capital cost schedule presented within the FBC now reflects robust equipment cost pricings.

## 4 | The Commercial Case

### 4.1 Introduction

This section of the FBC outlines the proposed procurement strategy in relation to the preferred option outlined in the Economic Case.

- ▶ Construction/ installation services.

### 4.2 Procurement Strategy

Key external advisors and construction services are as follows:

Table 17 Key External Advisors & Construction Services

Role	Organisation
<b>Pre-construction</b>	
Business case preparation	Trust
Mechanical and electrical consultants	Capita
Architects	P&HS
Structural engineers	Curtains
Cost consultants	RLB
CDM	Interserve
Trust project management & cost advisors	RLB
GMP development	Interserve Construction
<b>Construction</b>	
CDM	RLB
Project management & cost advice	RLB
Building contractor	Interserve Construction
MEP Detailed Design & Installation	Interserve Construction

Under the framework, Interserve Construction has:

- ▶ Taken single point responsibility to manage the design and construction process from completion of OBC through to project completion
- ▶ Assembled a dedicated team from its supply chain of experienced health planners, designers and specialists, to successfully deliver facilities that will benefit patients and staff alike
- ▶ Provided benefits of experience of long term partnering arrangements that will continue throughout the life of the project

- ▶ Committed to identifying construction solutions that will assist in the implementation of improved service delivery, best practice and delivering best value

Interserve Construction and UHL have worked together through the FBC stage to develop and agree a guaranteed maximum price (GMP) for delivery of the scheme. This reflects:

- ▶ Fees for professional advice such as design and cost management
- ▶ Market tested packages for construction works on an open book basis

The GMP has been received and falls within the value allowed within the cost allowances highlighted in sections 3 and 5. The GMP will now be assessed for overall value for money and affordability by cost consultants acting for UHL (Rider Levett Bucknall - RLB). This will take into account elements such as:

- ▶ Prevailing rates for similar works nationally and locally
- ▶ Published cost indices
- ▶ Knowledge of the cost of work in the hospital from other recent schemes
- ▶ Prime contractor and client retained risks as identified in the joint risk register

This assessment will be complete by Thursday 30<sup>th</sup> July 2015.

## 4.3 Risk

A detailed risk register has been developed throughout the FBC process which is regularly reviewed and updated. This is a combined risk register for all components of the vascular service move (Hybrid Theatre, Angiography Suite and VSU, and Ward) which includes common risks as well as those attributable to only one project. The latest version is attached at Appendix 4.

Risks will be classified as:

- ▶ Client – these will be the responsibility of the Project Board to manage and monitor
- ▶ Contractor – a project specific risk register will be set up for the Project. These will be the responsibility of the Contractor to monitor and will form part of the GMP

The qualification of the costs of identified risks will enable the calculation of a realistic client contingency.

A pro-active risk management regime will be employed throughout the project. It is essential on any project (in particular one of this size and complexity) that the risk management process involves all key members of the project team including:



- ▶ Trust Estates
- ▶ Trust FM
- ▶ Project Consultant Team
- ▶ Contractor
- ▶ Designers

For each identified risk the following are noted:

- ▶ Reference
- ▶ Category
- ▶ Risk and associated likely impact
- ▶ Probability and impact factors and associated overall risk rating
- ▶ Mitigation measures
- ▶ Cost and time impacts
- ▶ Risk owner and / or manager
- ▶ Action Date

Over time the allocation of the individual risks (Trust or PSCP) will also be reviewed to ensure risks are placed with the party best placed to deal with it.

## 4.4 Proposed Charging Mechanisms

The Trust intends to make payments in relation to works required in accordance with the Proposed Key Contractual Clauses.

## 4.5 Proposed Contract Lengths

A period of mobilisation would be required following approval of the FBC. The indicative construction programme reflected in the capital cost FB forms is 6 months (plus 1 months technical commissioning).

It is planned to raise the purchase order for the Vascular Ward, Angiography Suite, VSU and Hybrid Theatre on August 10<sup>th</sup> following Trust Board approval on August 6<sup>th</sup>, in order to meet the identified programme for construction.

## 4.6 Financial Reporting Standard 5 Accountancy Treatment

Any assets underpinning delivery of the service will be reflected on the Trust's balance sheet.



## 5 | The Financial Case

### 5.1 Introduction

The Financial Case examines the affordability of the options and sets out the financial implications for the Trust in terms of capital expenditure and cash flow, income and expenditure account and borrowing. The purpose of this section is to set out the forecast financial implications of the preferred options as set out in the Economic Case and the proposed deal (as described in the Commercial Case).

### 5.2 Capital Costs

The capital costs of the preferred option total £4.2m outturn and £3.4 m approval sum. Below is an analysis of the total costs.

Table 18 Summary of Capital Costs

Capital Costs	£
Construction	2,184,254
Fees	456,053
Non Works Cost	335,183
Equipment	118,158
Planning Contingency	117,331
Optimism bias	113,090
<b>Sub Total</b>	<b>3,324,069</b>
Inflation	840,833
<b>Total</b>	<b>4,164,902</b>

#### 5.2.1 VAT Recovery

Recoverable VAT has been assessed as follows:

Table 19 Recoverable VAT

	Value (£)	VAT (20%)	Recovery of VAT (%)	Total (£)	Comment
Works Cost	2,146,892	429,379	13.24%	56,834	Angiography and VSU based on VAT major refurbishment banding, Infrastructure non recoverable
PSCP fees	226,164	45,233	20%	9,047	Based on VAT major refurbishment banding
Trust fees	193,702	38,740	100%	38,740	100% recoverable
Non Works Costs					
Equipment	98,465	19,693	0%	0	
Planning Contingency (Trust Risk Generally)	97,776	19,555	0%	0	
Planning Contingency (Trust Risk Asbestos)					
PSCP Risk –	94,242	18,848	0%	0	
Inflation	700,694	140,139	0%	0	
Total	3,557,935	711,587	14.70%	104,621	

VAT recoverability assumptions have been based on discussions with the Trust's VAT advisers. The Trust will provide the agreed GMP to them, on which a submission to HMRC will be made.

## 5.2.2 Financing

The Trust has assumed the scheme will be funded through Interest Bearing Debt. The Trust requires funding in 2015/16 as the capital development is due for completion by April 2016.

## 5.3 Income and Expenditure

The table below summarises the current income and running costs associated with the Vascular Department together with the impact of the scheme on the current costs of the Vascular Department and the impact at Trust level. The baseline costs have been adjusted to reflect the transfer of the Vascular ward to Glenfield.

Table 23 Adult Vascular Services – Income & Expenditure

Baseline Costs	2015/16	2016/17	2017/18	2018/19	2019/20	2020/21
<b>Income</b>						
Vascular Tariff	7,493	7,493	7,493	7,493	7,493	7,493
<b>Total Income</b>	<b>7,493</b>	7,493	7,493	7,493	7,493	7,493
<b>Expenditure</b>						
Current Staff	3,699	3,819	3,819	3,819	3,819	3,819
Current Non pay	1,539	1,539	1,546	1,546	1,546	1,546
Current FM costs	102	102	102	102	102	102
Current Support costs	2,757	4,132	4,012	4,012	2,757	2,757
<b>Total Expenditure</b>	<b>8,097</b>	<b>9,591</b>	<b>9,479</b>	<b>9,479</b>	<b>8,224</b>	<b>8,224</b>
<b>Overheads</b>	<b>2,216</b>	<b>2,296</b>	<b>2,297</b>	<b>2,293</b>	<b>2,289</b>	<b>2,285</b>
<b>Total Current Costs</b>	<b>(2,819)</b>	<b>(4,394)</b>	<b>(4,282)</b>	<b>(4,278)</b>	<b>(3,019)</b>	<b>(3,015)</b>
<b>Angiography Income and Costs</b>	<b>2015/16</b>	<b>2016/17</b>	<b>2017/18</b>	<b>2018/19</b>	<b>2019/20</b>	<b>2020/21</b>
<b>Additional Income</b>		<b>88</b>	<b>88</b>	<b>88</b>	<b>88</b>	<b>88</b>
<b>Recurrent Costs</b>						
Vascular and Support Staffing		22	22	22	22	22
Non Pay		21	21	21	21	21
<b>Total Recurrent Costs</b>		<b>52</b>	<b>52</b>	<b>52</b>	<b>52</b>	<b>52</b>
<b>Depreciation &amp; Capital Charges</b>						
Change in Depreciation		15	15	15	15	15
Interest Payable	23	94	95	91	86	82
<b>Total Depreciation &amp; Capital Charges</b>	<b>23</b>	<b>108</b>	<b>109</b>	<b>105</b>	<b>101</b>	<b>97</b>

<b>Total Additional Cost</b>	<b>23</b>	<b>72</b>	<b>73</b>	<b>69</b>	<b>65</b>	<b>61</b>
------------------------------	-----------	-----------	-----------	-----------	-----------	-----------

The total additional costs of the scheme in the medium term are circa £60,000 - £70,000. This is driven by capital charges, additional staff of 0.5 WTE band 7 and equipment costs offset by additional screening income.

### 5.3.1 Workforce

The workforce change in this business case is minimal, and as above, only reflects an additional 0.5 WTE Band 7 post.

### 5.3.2 Capital Charges

The table below shows the basis of the capital charges calculation:

*Table 20 Capital Charge Impact of Scheme (IBD)*

<b>Angiography Capital Charges</b>	<b>2015/16</b>	<b>2016/17</b>	<b>2017/18</b>	<b>2018/19</b>
Opening Balance		3,673,443	3,931,319	3,764,029
Draw Down	3,748,411	416,490		
Loan Repayments	(74,968)	(158,613)	(167,290)	(167,290)
Closing Balance	3,673,443	3,931,319	3,764,029	3,596,739
Interest on loan (1 July 2015 rate 2.46%)	22,592	93,539	94,653	90,537
Depreciation		14,713	14,713	14,713
Total Capital Charges and interest	22,592	108,252	109,366	105,251

For comparison, the Trust has also modelled the use of PDC to fund the development rather than Interest Bearing debt. The position using PDC is as follows:

*Table 21 Capital Charge Impact of Scheme (PDC)*

<b>Angiography Capital Charges</b>	<b>2015/16</b>	<b>2016/17</b>	<b>2017/18</b>	<b>2018/19</b>
Return on Asset	32,143	4,892	4,377	3,862
Depreciation		14,713	14,713	14,713
Total Capital Charges (PDC)	32,143	19,606	19,091	18,576

Although the Trust would earn a high Rate of Return if the scheme was funded through PDC, this would be on the impaired asset rather than the PDC given itself and as a result the charge to I&E would be significantly lower than if the scheme was funded through IBD.

## 5.4 Impact on Trust Income, Cash Flow & Balance Sheet

The table below sets out the impact on the Trust's balance sheet.

Table 22 Impact on Trust's Balance Sheet

Impact on Trust's Balance Sheet	2015/16 £	2016/17 £	2017/18 £	2018/19 £
Opening Balance		3,748,411	132,420	117,707
Capital Expenditure	3,748,411	416,490		
Impairment		(4,017,768)		
Depreciation		(14,713)	(14,713)	(14,713)
Closing Balance	3,748,411	132,420	117,707	102,993

In addition to the above the Trust would be paying back the loan required to fund the scheme. It is assumed that £74,000 of loan repayment would be made in 2015/16 and then a figure of £167,000 per annum until 2041.

The new Angiography Suite and VSU is expected to be available in April 2016.

On coming into use, the Trust has assumed that as the development is refurbished estate, the only element which adds to value is the equipment. The basis of this as follows:

Table 23 Value of Impairments

	£
<b>Capital Cost</b>	<b>4,164,902</b>
Less Equipment	(147,134)
Revised Capital Cost Excluding Equipment	4,017,768
Planning contingency	146,105
Fees	567,893
Refurb	3,303,770
Total Impairment	4,017,768

## 5.5 Affordability

The scheme identifies a small net recurrent increase in revenue costs of c£70k per annum. This is driven by non-operating costs, i.e. capital charges and interest.

The Trust Financial Strategy, approved by the Trust Board on 4<sup>th</sup> June 2015, assumes the non-operating cost impact of the capital programme. It therefore includes these costs. The Angiography and VSU scheme identifies a small increase in costs of circa £70,000 per annum, driven by capital charges and interest.

### 5.5.1 Long Term Financial Model

The current 5 year LTFM which reflects the detail of the Financial Strategy approved by the Trust Board on the 4<sup>th</sup> June 2015 is constructed in a way which aggregates this development as part of the general site rationalisation service development. The assumptions regarding this service development include the operating costs impact of the developments will be zero.

As shown above, the case identifies only non-operating revenue costs increases and additional outturn capital costs of £0.8m. The revenue costs are therefore consistent with the LTFM whilst the capital cost increase will be mitigated across the total capital funding projection of c£330m.



# 6 | The Management Case


## 6.1. Introduction

The Management Case provides a summary of the arrangements which have been put into place for the successful delivery of the angiography suite and VSU, service operation changes, and to secure the benefits sought through the investment.

## 6.2. Project Governance Arrangements

Project Governance arrangements have been established to reflect national guidance and the Trust’s own Capital Governance Framework, as shown in the diagram below.

Figure 6 Vascular Angiography Suite & VSU Project Structure



4

5

6

6.1

6.2

### 6.2.1 Project Roles and Responsibilities

The Key Project roles are described below:

- ▶ Executive Sponsor / Senior Responsible Owner (SRO): This role is being performed by Kate Shields, with responsibility to the Executive Trust Board for delivery of the project to meet their terms of reference
- ▶ Project Board Chair: This role will be performed by Kate Shields for the Trust, with responsibility for providing impartial leadership of the project board and ensuring the continued commitment of stakeholders in order to deliver the collaborative approach required to deliver service efficiencies.
- ▶ Senior User: This role is being performed by Akhtar Nasim, Head of Service (Vascular Lead Clinician), with responsibility for ensuring that the project maintains alignment with the service and business targets described in the Business Case and working within the terms of reference set by the Project Board.
- ▶ Major Capital Projects Director: This role is being performed by Richard Kinnersley, Major Projects Technical Director with designated responsibility for all Capital Projects across UHL
- ▶ Project Manager: This role is being performed by Neal James with designated responsibility for delivering the FBC document. He will have day-to-day responsibility for administration of the development of the project (within the delegated role permitted by Project Board).
- ▶ Service Project Managers: Senior managers from the Vascular and associated departments will undertake this role, having day to day responsibility for providing advice on the service brief to the development team and for planning and delivery of service and workforce change under the direction of the Senior User.

Regular Progress Reports will be submitted to the Executive Strategy Board for onward reporting and management within the established Trust management structure

### 6.2.2 Core Group Responsibilities

The roles and responsibilities for the Core Groups are summarised as follows:

## Executive Strategy Board (ESB)

This group is a designated committee appointed by the Trust Board, with responsibilities which in summary, include:

- ▶ To advise the Trust Board on formulating strategy for the organisation.
- ▶ To ensure accountability by holding each other to account for the delivery of the strategy and through seeking assurance that all systems of control are robust and reliable.
- ▶ To lead the Trust executively, in accordance with our shared values, to deliver our vision and, in doing so, help shape a positive culture for the organisation

## Vascular Project Board

The Project Board at OBC stage was set up to manage the development of all the vascular components in a single case. Subsequent to the separation of the cases, it was deemed appropriate for the same forum to manage all three cases. Membership is as follows:

*Table 24 Vascular Project Board*

Project Team Member	Role
Kate Shields	Director of Strategy, Project Board Chair.
Akhtar Nasim	Consultant Vascular Surgeon, Service Lead
Richard Kinnersley	Major Projects Technical Director
Caroline Sissling	Operational Manager, Vascular Services
Carolyn Stokes	Service Manager, Vascular Services
David Jenkins	Consultant Microbiologist
Debra Green	Project Manager, Strategy
Elizabeth Collins	Infection Prevention Lead
Gaby Harris	ITAPS CMG
Guy Fishwick	Consultant Radiologist
Neal James	Project Manager
Kate Ward	Matron, Vascular Services
Judy Gilmore	Radiology Service Manager
Matthew Bown	Consultant Vascular Surgeon
Richard Power	CMG Clinical Lead, Musculoskeletal & Specialist Surgery
Sam Leak	CMG Lead, Renal, Respiratory & Cardiothoracic

Sarah Taylor

CMG Lead, Musculoskeletal &amp; Specialist Surgery

Key roles and responsibilities include:

- ▶ Responsibility for delivering the project within the parameters set within the business case
- ▶ Providing high level direction on stakeholder involvement and monitoring project level management of stakeholders
- ▶ Providing the strategic direction for the project
- ▶ Ensure continuing commitment of stakeholder support
- ▶ Key stage decisions
- ▶ Progress monitoring

### Vascular Work Streams

As shown in the Vascular Project structure, Figure 6, a number of work streams have been set up to ensure the successful development of the vascular project.

*Table 25 Work Streams & Deliverables*

Work Stream	Lead	Key deliverables
Operational (including key dependencies)	Ahktar Nasim (Consultant Vascular Surgeon & Head of Service)	Clinical / Operational Pathways (SOPs)
		Activity Scheduling
		Schedule of Accommodation / 1:200 Layouts
Workforce	Clare Blakemore (RRC CMG HR Lead)	Medical Staffing Rota implications
		Clinical Staff implications
		Recruitment
		Management of Change
		Cross-site Transfer
Finance	Tim Pearce	Capital Costing
		Enabling Costs
		Staffing Costs
		Revenue
		Financial Benefits
Procurement &	David Street	Fittings, Furnishings and Equipment

Work Stream	Lead	Key deliverables
Equipment	(Senior Category Manager)	General Equipment
		IM+T
Communications	Rhiannon Pepper (Communications Manager)	External and Internal Communications
Estates & Technical	Debra Green (Project Manager)	Site-wide Infrastructure
		Detailed design overview
		Construction

The work streams have been set up to take responsibility for driving the key work-streams and to report back to the Project Board on a regular basis.

Key roles and responsibilities will include:

- ▶ Day to day responsibility for the delivery of the project to meet the parameters described within the business case
- ▶ Provision of appropriate reports on status to the Project Director
- ▶ Management of risks and issues and escalation of appropriate matters for executive direction/ approval
- ▶ Providing working groups with detailed briefs
- ▶ Monitoring, co-ordinating and controlling the work of the Working Groups
- ▶ Drawing together the outputs of the Working Groups
- ▶ Ensure continuing commitment of stakeholders, both internal and external

## 6

### 6.1

#### 6.1.1

#### 6.2.3 Project Execution Plan

A Project Execution Plan (PEP) has been prepared (Appendix 5) to provide detailed information on proposed project management arrangements, including:

- ▶ Aims and objectives
- ▶ Benefits and constraints
- ▶ Organisation
- ▶ Roles and responsibilities
- ▶ Detailed programme for stage activities

- ▶ Risk management arrangements
- ▶ Statutory Approvals and Quality Standards
- ▶ Project Communications

The end stage of the project will result in the completion, handover and commissioning of the new facility. The Vascular Project Board is responsible for providing assurance that the project has been delivered in terms of product and quality in line with the business case.

## 6.3 Project Plan

The project will be managed in accordance with the principles of PRINCE2 methodology.

### 6.3

#### 6.3.1 Programme

##### 6.1

The Project Programme is intended to deliver the project by April 2016. The milestones for this project are set out below. A detailed programme is listed in Appendix 6.

*Table 26 Project Milestones*

Milestone	Date
Integrated Finance, Performance & Investment Committee support for FBC to be approved by Trust Board	July 30 <sup>th</sup> 2015
Trust Board Approval of FBC	August 6 <sup>th</sup> 2015
Purchase Order placed for construction	August 10 <sup>th</sup> 2015
Construction Commences	October 2015
Handover	April 2016

## 6.4 Use of Special Advisors

Special advisers have been used in a timely and cost-effective manner in accordance with the Treasury Guidance.

*Table 27 External Advisors*

Vascular & Hybrid Theatre Development

1	P&HS Design	Architects
2	RLB	Cost Consultants
3	RLB	Client Advisor: Project
4	Curtains	Structural Engineers
5	CAPITA	Mechanical and Electrical Engineers
6	RLB	PMO
7	Interserve	Building/Construction Supervisors
8	RLB	CDM
9	Interserve	BREEAM Advisor

## 6.5 Stakeholder Engagement

The following is a plan on the communications and engagement activities that will be collectively carried out during the project, in addition to wider program. The detailed plan can be found at Appendix 7.

2.19

2.20

2.21

2.22

2.23

### 6.5.1 Internal

- ▶ Face to face briefings: These should be used as the primary source of communication with staff
- ▶ INsite pages: A section on the Vascular project (Angiography Suite & VSU is a component part) can be included on the staff intranet pages
- ▶ Display boards/ Hoardings around building work
- ▶ Hospital Hopper: Information can be displayed aboard and on the exterior of the Hospital Hopper buses, which travel between the three UHL hospital sites.
- ▶ Factsheet style newsletter
- ▶ Blueprint & Chief Executive's Briefings: Utilise Blueprint reconfiguration newsletter for staff (bi-monthly) to update staff on progress.

## 6.5.2 External

- ▶ Social media: Utilising the Trust's Twitter and Facebook accounts
- ▶ Website: A section on the Vascular project (Angiography Suite & VSU is a component part) can be included on the UHL website, with a link from the homepage
- ▶ Local media
- ▶ Leicester Mercury Patient Panel: Panel made up of members of the public who provide comment on local issues
- ▶ Annual public meeting (September): Use this as an opportunity to share what has been accomplished and what is planned next
- ▶ Patient information leaflet

6.2

6.3

6.4

6.5

6.5.1

6.5.2

### 6.5.3 Infection Prevention

Representatives from UHL's Infection Prevention (IP) team, including the Lead IP Nurse and Consultant, have been fully engaged throughout the design development. IP representatives have provided guidance and signed off on all relevant aspects of the design.

### 6.5.4 Health & Safety

Representatives from UHL's Health & Safety team were consulted on the project and design solution. The size and layout of rooms throughout were reviewed in specific detail to ensure compliance for patient and staff safety.

## 6.6 Outline Arrangements for Change & Contract Management

Change management associated with the project will be managed through Trust Board, under the chairmanship of the Chief Executive / Senior Responsible Owner (SRO) and Executive Sponsor. Day to day change management issues will be discussed at the Project Team level and any resultant contract and / or cost changes will need to be approved by the Project Board.



## 6.7 Outline Arrangements for Benefits Realisation

The delivery of benefits will be managed through the Vascular Project Board. A benefits realisation plan has been described previously in Section 2.16. This sets out who is responsible for the delivery of specific benefits, when they will be delivered, and how achievement of them will be measured. The key opportunity is presented by the new design for facilities, which will ensure capacity meeting demand, efficiencies in service delivery, compliance to standards and minimised disruption to overall Trust operations.

## 6.8 Outline Arrangements for Risk Management

The Trust ensures through the involvement of its employees, that risk management serves as a mechanism for risk reduction. Also, by taking a proactive approach to managing risk exposure, the Trust ensures protection of its patients, staff, visitors, assets and reputation. This project will be managed in that context.

6.6

6.7

6.8

### 6.8.1 Risk Management Policy

The risk management system is described in the Trust's Risk Management Policy which is accessible to all staff via the Trust Intranet. It is based on an iterative process of:

- ▶ Identifying and prioritising the risks to the achievement of the organisation's policies, aims and objectives
- ▶ Evaluating the likelihood of those risks being realised and the impact should they be realised
- ▶ Managing the risks efficiently, effectively and economically

This is achieved through a sound organisational framework, underpinned by a robust policy framework, which promotes early identification of risk, the co-ordination of risk management activity, the provision of a safe environment for staff and patients, and the effective use of financial resources.

The Trust's Risk Register details, in order of relative importance, all the significant risks facing the Trust which are most likely to affect (positively or otherwise) achievement of the Trust's objectives.

All new Trust employees attend the corporate induction course, which includes elements of risk management, before they commence their duties in the workplace. This corporate induction is followed by a local induction, delivered by the service line manager, during which time staff receive information on risks specific to that service.

Risks are identified through feedback from many sources such as proactive risk assessments, adverse incident reporting and trends, clinical benchmarking and audit data, complaints, legal claims, patient and public feedback, stakeholder / partnership feedback and internal / external assurance assessments.

## 6.8.2 Assurance Framework

The Trust's Assurance Framework provides it with a simple but comprehensive method for the effective and focused management of the principal risks to meeting the Trust's corporate objectives. In this way it provides a structure and describes the controls and assurance mechanisms in place to manage the identified risks. This simplifies Board reporting and the prioritisation of action plans, which, in turn, allows for more effective performance management.

The key elements of the Assurance Framework are:

- ▶ Establishment of the Trust's principal objectives (strategic & directorate)
- ▶ Identification of the principal risks that might threaten the achievement of these objectives
- ▶ Identification and evaluation of the key controls intended to manage these principal risks
- ▶ Setting out of the arrangements for obtaining assurance on the effectiveness of the key controls across all areas of principal risk
- ▶ Evaluation of the assurance across all areas of principal risk
- ▶ Identification of the positive assurances and areas where there are gaps in controls and or assurances
- ▶ Putting in place of plans to take corrective action where gaps have been identified in relation to principal risks
- ▶ Maintenance of dynamic risk management arrangements including, crucially, a well-informed risk register

Therefore, the Assurance Framework provides a simple framework for reporting key information to Boards. It identifies which of the organisation's objectives are at risk because of inadequacies in the operation of controls or where the organisation has insufficient assurance about them. At the same time it provides structured assurances about where risks are being managed effectively and objectives are being delivered.

The primary focus is confidence that effective processes are in place to deliver the strategic objectives of the Trust. This allows Boards to determine where to make efficient use of their resources and address the issues identified in order to improve the quality and safety of care.

Where any significant gaps in assurance are identified they are transferred to the risk register and an action plan is developed.

## 6.9 Outline Arrangements for Post Project Evaluation

The outline arrangements for post Project Evaluation (PPE) have been established in accordance with best practice. The trust will ensure that a thorough post-project evaluation is undertaken at key stages in the process to ensure that positive lessons can be learnt from the project. These will be of benefit to:

- ▶ The Trust – in using this knowledge for future capital schemes
- ▶ Other key local stakeholders – to inform their approaches to future projects
- ▶ The NHS more widely – to test whether the policies and procedures used in this procurement have been used effectively
- ▶ Contractors – to understand the healthcare environment better

The evaluation will examine the following elements, where applicable at each stage:

- ▶ The effectiveness of the project management of the scheme – viewed internally and externally
- ▶ The quality of the documentation prepared by the Trust for the contractors and suppliers
- ▶ Communications and involvement during procurement
- ▶ The effectiveness of advisers utilised on the scheme
- ▶ The efficacy of NHS guidance in delivery the scheme
- ▶ Perceptions of advice, guidance and support from the strategic health authority and NHS Estates in progressing the scheme

Formal post project evaluation reports will be compiled by project staff, and reported to the Board to ensure compliance to stated objectives.

### 6.9.1 Post Implementation Review (PIR)

These reviews ascertain whether the anticipated benefits have been delivered and are timed to take place immediately after the angiography suite and VSU opens and then 2 years later to consider the benefits planned.

## 6.10 Contingency Plans

The Trust has a framework for Business / Service Continuity. The Trust's framework ensures the Trust can comply with the business continuity provisions of the Civil Contingencies Act 2004. Contingency plans have been developed to ensure the Trust can continue to deliver an acceptable level of service of its critical activities in the event of any disruption.

In terms of financial contingency, section 5 highlights a planning Contingency of 5% of the total costs, including fees and equipment, for short listed options.

## 6.11 External Review

Project Health Check reviews (previously known as Gateway reviews) provide a valuable perspective on the issues facing the internal project team, and an external challenge to the robustness of plans and processes. The process provides support to SROs by helping them to ensure the following:

- ▶ The best available skills and experience are deployed on the programme or project
- ▶ All the stakeholders covered by the programme or project fully understand the current status and the issues involved
- ▶ The programme or project can progress more confidently to the next stage of development, implementation or realisation
- ▶ Achievement of more realistic time and cost targets for the programme or project

A Health Check Review 3: Investment Decision was undertaken on both the ICU project and the vascular enabling moves; and associated report issued to the Project SRO on the 9<sup>th</sup> July 2015. A Delivery Confidence Assessment of AMBER was issued by the review team, indicating that: *“successful delivery of the project appears likely. However attention will be needed to ensure risks do not materialise into major issues threatening delivery”*.

Feedback specifically for Vascular services related to the need to ensure that all financial papers with the FBC document were complete and available for scrutiny as part of the IFPIC and Trust Board approval process.

# Appendices

Appendices are attached as separate documents and consist of the following:

Appendix	Details
1	Patient Survey Response
2	Due Regard / Quality Impact Assessment
3	Estates Annex
4	Full Risk Register (FBC stage)
5	Project Execution Plan
6	Project Programme
7	Communication and Engagement Plan

*Building Caring at its best*

**Full Business Case | Angiography & VSU**